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ABSTRACT
The photoreceptor phosphodiesterase (PDE6) plays an important role in the G-protein coupled
visual signaling pathway which uses cGMP as a second messenger to convert light stimuli into
electrical signals. PDE6 is a tetrameric peripheral membrane protein consisting of two catalytic
subunits and two inhibitory subunits and is localized to the outer segment membranes of rod and
cone photoreceptors. Mutations in this enzyme are one cause of retinitis pigmentosa and other
retinal degenerative diseases resulting in blindness or visual dysfunction that lack adequate
therapeutic intervention due to inadequate knowledge of PDE6 structure and regulation PDE6 is
tightly regulated in the nonactivated state, as well as during activation and deactivation of the
visual signaling pathway. In the nonactivated state, the rod PDE6 catalytic dimer (consisting of
the Pα and Pβ catalytic subunits) is inhibited by a pair of identical inhibitory subunits (Pγ) to
form the PDE6 holoenzyme (Pαβγγ). Activation of PDE6 results from displacement of the Pγ
subunit by the light-activated G protein alpha-subunit (Gtα). Deactivation of PDE6 is the result
of the GTPase activity of Gtα which is aided by a GTPase accelerating complex consisting of the
Regulator of G Protein Signaling 9 (RGS9-1), the obligate dimer to RGS9-1, Gβ5L, and the
RGS9-1 anchoring protein (R9AP). Together this inactivation complex allows PDE6 to return to
the nonactivated conformation. The hypotheses of my research are: (1) silica particles encased by
large unilamellar phospholipid vesicles will mimic the photoreceptor membrane and provide a
surface suitable for enhancing the interactions of PDE6 and Gtα as well as the proteins involved
in the deactivation complex; (2) one Gtα molecule binds to each PDE6 catalytic domain and
induces a large conformational change in the inhibitory Pγ subunit; (3) interaction of RGS9-1
with Gtα will induce changes in the interaction surface between activated Gtα and PDE6,
allowing Pγ to resume the conformation which inhibits PDE6 activity.
xii

The first aim of my research is to establish a methodology to study PDE6 and its associated
complexes in a system that mimics the rod outer segment. In order to achieve this, a protocol for
encasing silica particles in large unilamellar phospholipid vesicles (called “lipobeads”) was
developed. This methodology not only allowed for an increase in the extent of Gtα activation
when compared to PDE6 in solution, but also allowed for study of membrane-attached PDE6 and
Gtα at concentrations that more closely mimic those observed in the rod outer segment.
The second aim of my research is to characterize the structure of membrane-attached PDE6 in its
nonactivated state and in the fully activated state upon binding of Gtα. This was achieved using
chemical crosslinking and mass spectrometry in conjunction with a computational modeling
program called the Integrative Modelling Platform. In the nonactivated state, it was observed the
Pγ has significant interaction with the regulatory GAFa domain as well as the catalytic domain of
Pαβ while displaying a less well defined structure in the central cationic region of Pγ. Upon
activation, two Gtα are bound to specific docking sites on PDE6 resulting in the displacement of
Pγ from both catalytic domains as well as a predicted shift of Pγ away from GAFa.
The third aim of my research is to understand the sequential activation mechanism of PDE6 by
Gtα. Chemical crosslinking and mass spectrometry was again used in order to characterize the
structures of PDE6 with a sub-stoichiometric amount of Gtα as well as a slight stoichiometric
excess of Gtα (0.4:1 and 3:1 Gtα:PDE6, respectively). In the case of the stoichiometric excess, a
high molecular weight cross-linked band on SDS-PAGE indicative of two Gtα bound to PDE6
was structurally analyzed; the sub-stoichiometric condition resulted in a single Gtα bound
species which was also analyzed. Comparisons were also made between the inactive (Gtα-GDP)
and activated (Gtα*-GDP-AlF4-) states. This work showed that when two activated Gtα*
molecules were bound to PDE6 both Gtα subunits were associated with the catalytic domains of
xiii

PDE6. When Gtα was present at sub-stoichiometric levels relative to PDE6, a single docking
site was identified in proximity to the GAFb domains of PDE6. The inactive state of Gtα (GtαGDP) also was capable of binding PDE6 but bound only to the GAFb domains. Measurements of
PDE catalytic activity established two Gtα-GDP-AlF4- molecules were able to produce
significant activation of PDE6, whereas the sub-stoichiometric condition (0.4 Gtα per PDE6) did
not produce activity above basal levels. These results indicate that the binding of a single Gtα is
not sufficient to stimulate activity of PDE6.
The final aim of my research is to establish a methodology for the study of the deactivation
complex of PDE6. To achieve this aim, lipobeads were used in order to anchor the integral
membrane protein R9AP to produce “proteolipobeads”. This membrane-embedded R9AP
preparation was then able to bind the RGS9-1/Gβ5L without affecting the ability of PDE6 and
Gtα to also bind to the proteolipobeads. Chemical crosslinking and mass spectrometry analysis
confirmed that all of the proteins were present on the membrane and in close enough proximity
to allow future analysis of the PDE6 inactivation complex.

xiv

INTRODUCTION
1: Visual signal transduction
1.1 Visual Excitation
Both rods and cones contain outer segments where visual transduction takes place which
is triggered when light enters the eye and stimulates the photoreceptor cells of the retina. Visual
signaling is initiated by photopigments, consisting of a protein called opsin and a small,
covalently attached chromophore (11-cis-retinal) (Nathans, 1999; Stenkamp et al., 2002). In
mammals, rods only have one type of photopigment, rhodopsin whereas cones have up to four
classes of visual pigments in mammalian cone photoreceptors: LWS, MWS, SWS1 and SWS2
(Hofmann and Palczewski, 2015). The wavelength sensitivity of the photopigment is determined
by the amino acid composition of opsin in the vicinity of the chromophore binding site which has
the effect of altering the spectral tuning of the visual pigment.
In both rods and cones, in the absence of light the visual signaling pathway proteins are
inactive, the concentration of cGMP and calcium is relatively high and the plasma membrane is
depolarized. Upon photon absorption by rhodopsin, isomerization of 11-cis retinal to all-trans
retinal occurs which induces a conformational change in opsin allowing for interaction with the
G-protein (transducin) on the disk membrane. This interaction results in the exchange of GDP
for GTP in the α-subunit of transducin (Gtα). GTP-bound Gtα dissociates from the βγ subunits of
transducin and is able to then activate PDE6. Activated PDE6 hydrolyzes cGMP to 5’-GMP,
resulting in a decrease in cGMP concentration which in turn causes cGMP-gated ion channels to
close. The closure of cGMP-gated ion channels prevents Na+ and Ca+2 from entering the cell and
thus causes hyperpolarization of rod outer segment plasma membrane, which is propagated
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through the length of the photoreceptor cell to inhibit the release of neurotransmitter at the
photoreceptor synaptic terminal (Zhang et al., 2005).
1.2. Inactivation of visual excitation
In order to recover to the dark-adapted state after light exposure, the visual signaling
pathway needs to be shut off efficiently and reproducibly. To recover the dark-adapted state of
the rod photoreceptor, three proteins in the visual signaling pathway need to be deactivated
(rhodopsin, transducin, and PDE6) along with activation of guanylyl cyclase to restore cGMP
levels.
1.2.1 Deactivation of rhodopsin
Deactivation of rhodopsin involves a photoreceptor-specific G-protein-coupled kinase,
rhodopsin kinase (GRK1), which phosphorylates light-activated rhodopsin. This is followed by
arrestin binding to the phosphorylated rhodopsin (Maeda et al., 2003). GRK1 has an "RH-kinase
core" wherein a Ser/Thr kinase domain is inserted into a loop of a regulator of G protein
signaling homology (RH) domain (Tesmer, 2009). Of note, the phosphorylation of the Cterminal serine and threonine initiate the uncoupling of rhodopsin from transducin (Zhang et al.,
1997). An inactivating mutation of GRK1 was identified in Oguchi disease, a form of stationary
night blindness, which supported a central role of GRK1 in vision (Dryja, 2000). Besides GRK1,
most mammalian cone photoreceptors also express GRK7 which play an important role for
deactivation of cone opsins. The presence of GRK7 in cones explains why patients with Oguchi
disease have difficulty seeing in dim light but only exhibit relatively mild defects in conemediated vision (Chen et al., 2001; Wada et al., 2006; Weiss et al., 2001).
GRK1 activity is regulated by the Ca2+-sensor protein, recoverin (Chen et al., 1995;
Kawamura & Tachibanaki, 2008; Klenchin et al., 1995). Recoverin is a small calcium (Ca 2+)2

binding protein which belongs to neuronal calcium sensor (NCS) family (Ames & Lim, 2012;
Burgoyne & Haynes, 2012). Recoverin binds to and inhibits GRK1 in a calcium dependent
manner, allowing for regulation of GRK1 activity (Chen et al., 1995). Besides regulation by
rhodopsin and recoverin, GRK1 is also regulated by protein kinase A (PKA) phosphorylation. In
vitro assays revealed that the sites in the amino terminus of GRK1 and GRK7 (Ser21 and Ser36,
respectively) can be phosphorylated by PKA (Horner et al., 2005). GRKs phosphorylated by
PKA showed decreased ability to phosphorylate rhodopsin. GRK phosphorylation by PKA is
high in the dark and low in the light, consistent with the cAMP concentration change under
different light conditions (Osawa et al., 2008). This provides another mechanism regulating the
lifetime of activated rhodopsin.
Binding of arrestin to GRK1-phosphorylated rhodopsin is required for blocking
transducin heterotrimer interaction with rhodopsin. Mammals have four types of arrestins.
Arrestin-1 and -4 are specifically expressed in rod and cone photoreceptors, respectively.
Arrestin-1 is the second most abundant signaling protein after opsin in photoreceptor cells
(Hanson, Gurevich, et al., 2007; Nikonov et al., 2008; Song et al., 2011; Strissel et al., 2006). It
has two all-β-strand domains (Granzin et al., 1998; Hirsch et al., 1999). Among all the signaling
proteins in rods, only arrestin-1 self-associates at physiological concentration, forming dimers
and tetramers (Hanson, et al., 2007; Imamoto et al., 2003; Schubert et al., 1999). Biochemical
studies showed that only monomeric arrestin-1 binds rhodopsin while oligomers do not (Hanson,
et al., 2007). Both in vitro (Vishnivetskiy et al., 2007) and in vivo (Mendez et al., 2000)
experiments revealed that arrestin requires three phosphates on rhodopsin for high-affinity
binding, but does not care which particular residues out of six (mouse) or seven (bovine) serines
and threonines are phosphorylated. Site-directed mutagenesis identified multiple positively
3

charged arrestin-1 residues interacting with receptor-attached phosphates (Gurevich & Benovic,
1995, 1997; Sutton et al., 2005).
The specialized nature of the photoreceptor cell, with a light-harvesting outer segment
connected by a connecting cilium to the inner segment (where most cellular organelles reside),
requires regulated transport of proteins between these two compartments. For example, in the
dark-adapted state, the concentration of arrestin in rod outer segment is low, and most arrestin
resides in the inner segment in association with microtubules (Hanson, Cleghorn, et al., 2007;
Nair et al., 2005). The fraction of total arrestin in the dark-adapted rod outer segment is
estimated to be ~20% by immunohistochemistry (Hanson, Gurevich, et al., 2007; Nair et al.,
2005). Upon illumination, visual arrestin translocates from photoreceptor cell bodies to outer
segment where it quenches activated rhodopsin. However, both the mechanism and function of
arrestin translocation are unresolved and controversial (Satoh et al., 2010).
1.2.2 Deactivation of transducin
Like all other G protein α-subunits, activated Gtα has an intrinsic GTPase activity so it
can hydrolyze bound GTP to GDP, and then reassociate with the transducin βγ dimer to form the
inactive, heterotrimeric G-protein. Since PDE6 activation is directly dependent on association
with Gtα-GTP, the lifetime of PDE6 activation is dictated by the GTPase rate of Gtα. However,
the intrinsic rate of GTP hydrolysis by transducin α-subunit is too slow by ~100-fold to control
signal termination of a photoresponse (Arshavsky & Pugh, 1998), and this observation provided
evidence for the existence of a GTPase accelerating protein (GAP) (Arshavsky et al., 1989;
Arshavsky & Pugh, 1998)
The GAP responsible for transducin regulation during the visual signaling pathway
consists of a complex of three proteins: RGS9-1, its obligate binding partner Gβ5L, and the
4

integral membrane anchoring protein, R9AP (Hu & Wensel, 2002). R9AP is a transmembrane
protein that enhances the ability of RGS9-1/Gβ5 to inactivate Gtα by increasing the rate of GTP
hydrolysis (Baker et al., 2006; Hu & Wensel, 2002; Lishko et al., 2002) and protects RGS91/Gβ5L from intracellular proteolysis (Keresztes et al., 2004; Krispel et al., 2006).
In addition to deactivation by the RGS9 complex, Gtα also regulates the visual signaling
pathway by translocation between the inner and outer segments in rod cells. The triggering of
transducin translocation requires relatively bright light intensities (10,000 rhodopsin
photoactivated per rod per sec (Sokolov et al., 2002)), and occurs in what appears to be a
diffusion driven mechanism (Calvert et al., 2006). Transducin is membrane-associated due to
post-translational modifications on its γ-subunit (farnesylation) and its α-subunit (acylation).
Upon transducin activation upon illumination of the photoreceptor cell, transducin α-subunit
dissociates from the βγ subunits resulting in each subunit becoming more soluble because each
has only one lipid modification (Seitz et al., 1999), enabling them to diffuse to the inner segment
from the outer segment. Upon GTP hydrolysis by Gtα, it can reassociate with βγ subunits to form
the tightly membrane-bound trimer. It has been found that the translocation rates of transducin αand βγ-subunits are different, supporting the idea that transducin trimer dissociates before
translocation (Sokolov et al., 2002). Interaction of transducin βγ with an abundant photoreceptorspecific protein, phosducin, further reduces its membrane affinity and enhances its translocation
(Sokolov et al., 2004; Yoshida et al., 1994).
1.2.3: Regeneration of Visual Pigment
Dark adaptation is the process of reversing the changes that occurred during light
excitation and preparing photoreceptors for the next photoactivation event. During
photoactivation, 11-cis retinal covalently bound to opsin undergoes photoisomerization to all5

trans-retinal, and this process need to be reversed during dark adaptation. The biochemical
process to regenerate 11-cis retinal is called the retinoid cycle, which requires the participation of
a monolayer of highly polarized epithelial cells adjacent to the retina, called the retinal pigment
epithelium (RPE) (Smith et al., 2016).
The first step of the visual cycle is dissociation of all-trans-retinal from photo-activated
rhodopsin and the release of all-tran-retinal into the disk membrane (Palczewski, 2006). The alltrans-retinal is flipped across the membrane by the retinal-specific ATP-binding cassette
transporter (ABCA4) and then reduced to all-trans-retinol by all-trans-retinol dehydrogenases
(all-trans-RDHs). The hydrophobic nature of retinoids limit their aqueous diffusion and hence
transportation of all-trans-retinol from photoreceptors to RPE is facilitated by a soluble
lipoglycoprotein in the interphotoreceptor matrix, called interphotoreceptor-binding protein
(IRBP). In the RPE, all-trans-retinol is chaperoned by cellular retinol-binding protein (CRBP)
and is esterified by lecithin-retinol acetyl transferase (LRAT) localized in the endoplasmic
reticulum, where the all-trans-retinol is isomerized by retinoid isomerase (RPE65) to 11-cisretinol. 11-cis-retinol is then oxidized to 11-cis-retinal and is then chaperoned by
interphotoreceptor retinoid-binding protein (IRBP) where it can be conjugated to opsin to
regenerate the visual pigment (Kiser et al., 2014; Kiser et al., 2012).
2. Biochemical insights into the mechanism of Gtα activation of PDE6
This section will summarize the biochemical evidence for the mechanism by which
transducin binds to and activates rod PDE6 during phototransduction and then will apply that
evidence to the structural studies of the Gtα-PDE6 activation complex to shed light on the
sequence of steps progressing from nonactivated PDE6 to the fully activated enzyme.
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2.1 Activation by transducin is enhanced when Gtα and PDE6 are membrane-associated
It is well established that Gtα activation of PDE6 occurs with greater efficiency when
transducin and PDE6 are tethered to the rod outer segment membrane (or phospholipid bilayers)
by their fatty acyl and prenyl groups, respectively (Malinski & Wensel, 1992; Melia et al., 2000).
Gtα is acylated at its extreme N-terminal glycine residues which facilitates membrane attachment
(Neubert et al., 1992). Gtα has heterogeneity in its acyl modification which may result in the
observation that only a portion of Gtα exhibits high affinity binding to membranes (Gray-Keller
et al., 1990; Wensel & Stryer, 1988). Co-localization of Gtα* and PDE6 on membranes
potentially serves to optimize the activation mechanism, both by creating a high local
concentration of protein as well as reducing the dimensionality of diffusional encounters.
2.2. Gtα-activated PDE6 can attain the same maximal extent of activation as the Pαβ
catalytic dimer lacking Pγ
There have been a wide range of maximal extents of Gtα activation of PDE6 catalytic
activity but the preponderance of evidence supports the idea that when both proteins are
membrane-associated and a sufficient amount of Gtα is present, PDE6 can be activated by Gtα in
vitro to a similar extent as Pαβ catalytic dimers devoid of Pγ (Bennett & Clerc, 1989; Liu et al.,
2009; Melia et al., 2000). Whether full catalytic activation of PDE6 by transducin occurs in vivo
is still a matter of debate.
2.3 Alteration in cGMP binding upon transducin activation
Two different mechanisms in which successive binding of two Gtα to PDE6 fully
activates catalysis have been proposed. These mechanisms differ in whether the two binding
events of Gtα occur with equal (Wensel & Stryer, 1990) or different (Bennett & Clerc, 1989; Liu
et al., 2009; Min et al., 2000) affinities for PDE6. One such mechanism has been proposed
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(Qureshi et al., 2018) which involves a two-stage process: (1) high-affinity binding of the first
activated Gtα*-GTP to PDE6 but with little catalytic activation of PDE6; (2) low-affinity binding
of a second Gtα*-GTP which results in full activation (i.e., equivalent to Pαβ lacking bound Pγ)
at both active sites. This mechanism is not only consistent with the structural and functional
asymmetry of the rod PDE6 catalytic heterodimer and its nonidentical binding interactions with
its two Pγ subunits, but also is supported by computational simulations of the photoresponses of
mammalian rod photoreceptors to dim and bright illumination (Lamb & Kraft, 2020; Lamb et al.,
2018).
Binding of Gtα to PDE6 relieves Pγ inhibition of catalysis in the catalytic domain and
also enhances the rate at which cGMP exchange occurs at the binding sites in GAFa (Zhang et
al., 2012). Since the Pγ N-terminal region enhances cGMP binding affinity to the GAFa
domains (Mou & Cote, 2001), this effect of Gtα has been attributed to Gtα binding to Pγ and
disrupting the interactions of the N-terminal region of Pγ with the GAFa domain.
3. Structural studies of the Gtα*-PDE6 complex
Two recent structural determinations of the activation complex of Gtα with PDE6 (Gao et
al., 2020; Irwin et al., 2019) provide two distinct mechanisms by which Gtα activates PDE6. The
approach used by Irwin et al. employed chemical cross-linking and mass spectrometric analysis
combined with integrative structural modeling that identified two distinct docking sites on each
PDE6 catalytic subunit for Gtα, one interacting with the catalytic domain and the other site
interacting with the GAFb domain (Irwin et al., 2019). Gao et al. utilized high-resolution cryoEM analysis of the Gtα*-PDE6 complex which identified Gtα interacting only with the GAFb
domains (Gao et al., 2020). A detailed discussion of these structural models is presented in later
chapters.
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Figure 1-1. Graphical abstract presented in Gao et al. (2020) showing the binding of two
Gtα to PDE6
3.1.1. Overview of the PDE6 holoenzyme
In order to elucidate the structure-function relationship of PDE6, there has been a
significant effort to determine the structure of the PDE6 holoenzyme and its associated
complexes. However, the inability to express rod PDE6 recombinantly has limited the study of
the atomic-level structure of PDE6. Recently, there have been several high resolution cryo-EM
structures published at 11 Å and 3.4 Å resolution (Zhang et al., 2015; Gulati et al., 2019). In one
case, the cryo-EM resolution was sufficient to determine the position of the N- and C-terminal
fragments of Pγ (Gulati et al., 2019).
In addition to cryo-EM, cross-linking with mass spectrometry (XL-MS) has been used to
determine a homology model for the Pαβ structure of the holoenzyme (Zeng-Elmore et al.,
2014). The homology model as well as the cryo-EM structure agree on the defining
characteristics of PDE6; (1) there is an N-terminal “pony tail” region where Pα and Pβ seem to
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wind together (2) the GAF domains of one subunit are located adjacent to the catalytic domain of
the other subunit (3) there is significant disorder present in the GAFb domains of Pα and Pβ.
3.1.2 Structure and function of the inhibitor γ-subunit of PDE6
PDE6 is the only family of Class I phosphodiesterases whose catalytic activity is
regulated by a distinct protein subunit, Pγ. Most of the sequence diversity between rod and cone
Pγ isoforms is found in the N-terminal region of the protein, along with four highly conserved
rod-cone differences at positions 21, 48, 74, and 84 of the rod Pγ sequence (Wang et al., 2019).
In non-activated PDE6, catalytic activity is suppressed by two Pγ subunits that physically
prevent substrate access to the enzyme active site on each catalytic subunit (Barren et al., 2009;
Granovsky et al., 1997). Upon photoactivation of the visual excitation pathway, Gtα*-GTP binds
to Pγ, relieving its inhibitory constraint and activating PDE6 (Arshavsky et al., 2002). During
photoresponse recovery, the Pγ subunit also interacts with the Regulator of G-protein
Signaling9-1 (RGS9-1) to accelerate the intrinsic GTPase activity of Gtα*-GTP that leads to the
restoration of PDE6 to its inhibited state (reviewed in (Arshavsky & Wensel, 2013)).
The ability of the Pγ subunit to carry out its many functions is a consequence of Pγ exhibiting
the structural properties of an intrinsically disordered protein. The 87 amino acid sequence of
rod Pγ is largely devoid of secondary structure (Uversky et al., 2002). The NMR solution
structure of rod Pγ was determined to consist of an unfolded N-terminal region; similar results
were observed for the N-terminal half of cone Pγ (Gupta et al., 2020) with only three small αhelical segments that interact with the catalytic domain (Song et al., 2008). The Pγ subunit
assumes a linearly extended conformation upon binding to Pαβ (typical for intrinsically
disordered protein) with its N-terminal region interacting with the GAFa domain, the central
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polycationic region interacting with the GAFb domain, and the glycine-rich and C-terminal
regions (containing α-helical content) binding to the catalytic domain.
4. Structural analysis of transducin and the transducin α-subunit
There have been several studies focused on the structural determination of transducin and
the transducin α-subunit (Gtα). X-ray crystallography was used, and in each case the N-terminal
α-helix (including the site of N-terminal acylation) was removed prior to structural
determination. These studies found that there is minimal structural differences between the GDPbound Gtα in a reconstituted heterotrimer, GDP-bound Gtα free in solution, and persistently
activated Gtα (Lambright et al., 1994, 1996; Noel et al., 1993; Sondek et al., 1994). Additionally,
a study by Slep et al. (2001) determined the structure of Gtα complexed with the RGS domain of
RGS9 as well as a fragment of the PDE6 inhibitory subunit Pγ (Slep et al., 2001). In each of
these studies, the overall conformation of Gtα did not vary significantly, indicating that Gtα
likely posses a fairly static structure under crystallization conditions.
5. Structural studies of transducin-PDE6 activation complex
Gao et al. (Gao et al., 2020) provided the first high-resolution cryo-EM structure of the
Gtα-PDE6 activation complex (PDBID: 7jsn), which shows the Gtα subunits located in the
vicinity of the GAFb domains. The model was produced using a chimeric G protein α-subunit
consisting of Gtα with substitutions of Gi α-subunit residues that enabled bacterial expression
(Giα/Gtα). The Gao et al. structure identified interactions with the β5/β6 loops of both GAFa and
GAFb of Pα and the GAFb α1/α2 helices and α11 of the catalytic domain of the Pβ subunit. The
N-terminal half of Pγ retained a very similar conformation to that of nonactivated PDE6
holoenzyme, but the polycationic, glycine-rich, and C-terminal regions of Pγ show major
displacement of Pγ from its sites of interaction in the nonactivated PDE6 holoenzyme (Gao et al.,
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2020).The C-terminal residues of Pγ undergo an ~60 Å movement upon binding to Gtα, with the
C-terminal region of Pγ interacting with the Switch II and Switch III elements of Gtα, similar to
the conformation observed in the RGS9-1 inactivation complex (Slep et al., 2001).
From this model Gao et al. proposed an alternating-site activation mechanism where both
Gtα subunits are associated with the GAFb domains in a complex with Pγ, inducing allosteric
catalytic activation of one PDE6 subunit at a time. They proposed that binding of the Ras subdomain of the first Gtα to Pγ removes the C-terminal region from the catalytic domain to form a
stable interaction with the GAFb domain without inducing catalytic activation. Upon binding of
the second Gtα, catalytic activation ensues in an alternating mechanism with one active site at a
time. Gao et al. proposed that the GAFb domain of PDE6 and the helical sub-domain of Gtα
allosterically regulate which PDE6 catalytic domain is active (for details, see Fig. 6 of Gao et al.,
2020).
Limitations of the Gao et al. (Gao et al., 2020) structure of the Gtα-PDE6 activated
complex include: (1) a chimeric G-protein consisting of 18 G iα residues substituted into the
transducin Gtα sequence which could change its interactions with PDE6; (2) tethering the two
chimeric Giα/Gtα* subunits together with an antibody may have imposed steric restraints which
restrict the number of orientations that Gtα could productively bind to PDE6; (3) use of
vardenafil (a PDE5/6 inhibitor) likely weakened Pγ interactions with the catalytic domain
(Barren et al., 2009; Gillespie et al., 1989; Granovsky et al., 1997; Zhang et al., 2005) and as a
consequence may have enhanced the ability of Gtα to displace the C-terminal residues of Pγ
from the active site in a non-physiological manner.
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In chapters 3 and 4, I present an alternative hypothesis based on my own research. In
brief, I will show that the initial docking site of Gtα resides on the GAFb domain, consistent with
the work of Gao et al. However, this docking site only appears to be present when a single Gtα
is bound and results in very little catalytic activation of PDE6. When two Gtα are bound to
PDE6, the docking sites shift to the catalytic domain and PDE6 catalytic activation occurs. Our
results support a sequential mechanism of activation upon Gtα binding to PDE6 resulting in both
catalytic subunits being activated simultaneously.
6. Conclusion
The overall goal of my doctoral research is to elucidate the mechanism by which Gtα
activates PDE6 to provide insights into the interactions occurring during phototransduction that
may ultimately lead to developing therapeutic interventions for inherited retinal degenerative
diseases. The central hypothesis of my work is that two Gtα interacting primarily with Pγ on
PDE6 are required for full activation of PDE6. The specific aims of my project are to: (1)
establish a methodology to study PDE6 and its associated complexes in a system that mimics the
rod outer segment; (2) to characterize the structure of membrane-associated PDE6 in its
nonactivated and in the fully activated complex of Gtα-PDE6; (3) elucidate activation
mechanism of PDE6 by Gtα; and (4) establish a methodology for the future study of the
deactivation complex of PDE6.
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CHAPTER 2
RECONSTITUTION OF MEMBRANE-ASSOCIATED COMPONENTS OF A GPROTEIN SIGNALING PATHWAY ON MEMBRANE-COATED NANOPARTICLES
(LIPOBEADS)
Some of the content in this chapter is a manuscript in preparation.
Authors: Michael J. Irwin, Xin Wang, Rick H. Cote
Abstract
G-protein coupled signaling pathways are organized into multi-protein complexes called
signalosomes that are organized within and on cellular membranes. We describe the use of silica
nanoparticles coated with a unilamellar phospholipid bilayer (lipobeads) to reconstitute the
activated photoreceptor G-protein α-subunit (Gtα*) with its cognate effector (phosphodiesterase6; PDE6) for biochemical and structural studies of the activation mechanism of this GPCR
signaling pathway. Lipobeads are prepared by resuspending dried-down phospholipid mixtures
with monodisperse, 70 nM silica particles followed by extrusion through a 100 nm membrane
filter. This uniform, supported liposomal preparation is easily sedimented, permitting separation
of soluble from membrane-associated proteins. Upon loading lipobeads with Gtα* and PDE6, we
find that activation of PDE6 catalysis by Gtα* occurs much more efficiently than in the absence
of membranes. Chemical cross-linking of membrane-confined proteins allows detection of
changes in protein-protein interactions resulting from G-protein activation of PDE6. The
advantages of using lipobeads over traditional liposomal preparations are generally applicable to
the study of other membrane-confined signal transduction pathways.
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1. Introduction
1.1 Heterotrimeric G-protein coupled signaling pathways are organized in macromolecular
complexes (signalosomes)
G-protein coupled receptor (GPCR) signaling pathways consist of protein complexes
(signalosomes) associated with the cell membrane that form dynamic supramolecular structures.
During signal transduction, these integral and peripheral membrane proteins undergo
assembly/disassembly reactions and structural rearrangements that result in allosteric changes in
protein-protein interactions, enzymatic activity and/or changes in membrane localization.
Understanding the mechanistic processes underlying operation of GPCR signaling assemblies
has been hampered by the difficulty of reconstituting these signalosomes with phospholipid
bilayers in order to define the sequence of events occurring during receptor activation by its
ligand(s), activation of G-proteins, binding to activated G-protein subunits to their effectors, and
the subsequent reactions that terminate the activated state of the signalosome.
Whereas much progress has been recently been made in high-resolution structures of
GPCRs complexed with their cognate G-proteins (for review, see ref. (Zhou et al., 2019)), there
are few structural studies of the downstream signaling complexes resulting from interactions of
activated G-protein subunits with their effectors on the membrane surface. For example,
although phospholipase C-β3 and Gqα are normally associated with the cell membrane, the
atomic-level structure was determined as a soluble complex (Lyon et al., 2013) whose molecular
architecture may differ from the Gqα-PLC-β3 complex attached to the membrane. A more recent
cryo-EM study of detergent-solubilized adenylyl cyclase-9 (AC9, an integral membrane protein)
bound to activated Gsα revealed the interaction surface of this G-protein-effector complex, with
the membrane-spanning helical bundle of AC9 embedded in detergent micelles (Qi et al., 2019).
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Although cryo-EM is ideally suited to determine the structures of larger proteins and protein
complexes, it remains challenging for numerous reasons to study integral and peripheral
membrane proteins in their membrane-associated state with this approach (Akbar et al., 2020).
1.2 Most components of the visual transduction signalosome in vertebrate rod and cone
photoreceptors are membrane-confined.
Visual transduction in vertebrate rod and cone photoreceptor cells is a prototypical Gprotein coupled signaling pathway. The visual excitation pathway occurs upon photoactivation
of the visual pigment, rhodopsin, which leads to the activation of the photoreceptor-specific Gprotein (transducin) α-subunit (Gtα), and subsequent activation of its effector, cGMP
phosphosdiesterase-6 (PDE6) (Cote, 2021). The signal-transducing outer segment of the rod
photoreceptor cell consists of densely packed membranes that contain a high surface density of
rhodopsin (to maximize photon capture), as well as Gtα and PDE6 (Molday & Moritz,
2015). The rate-limiting step in signal termination involves proteins that regulate the activated
lifetime of Gtα, namely the Regulator of G-protein Signaling9-1 (RGS9-1), G-protein βsubunit5-L (Gβ5L), and the RGS9-1 anchoring protein (R9AP) which tethers this inactivation
complex to the outer segment membrane (Arshavsky & Wensel, 2013). Proteomic profiling of
highly purified rod outer segment disk membranes confirm that both the activation complex
(Gtα-PDE6) and inactivation complex (RGS9-1-Gβ5L-R9AP) are membrane-confined, either as
integral membrane proteins (rhodopsin, R9AP), lipidated peripheral membrane proteins (Gtα,
PDE6), or as soluble proteins very tightly associated with R9AP (RGS9-1, Gβ5L) (Skiba et al.,
2013).
Although detailed quantitative models of the visual transduction pathway have been
developed that integrate electrophysiological and biochemical data (Lamb & Kraft, 2020), the
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structural biology and conformational dynamics of the membrane-confined photoreceptor
signalosome are poorly understood. Whereas atomic-level structures for rhodopsin (in various
liganded states) and transducin have been available for some time, we still lack threedimensional structures of the activated complex of rhodopsin with Gtα (although structures of
rhodopsin complexed with the homologous Giα subunit (Kang et al., 2018) or with a chimeric
Gtα/Giα subunit (Gao et al., 2019; Gao et al., 2017) have been reported). Likewise, the overall
structure of the soluble form of the hetero-tetrameric rod PDE6 holoenzyme has been determined
to near atomic-level resolution (Gulati et al., 2019; Qureshi et al., 2018; Zeng-Elmore et al.,
2014); however, the molecular organization of the Gtα-PDE6 activated complex in its
membrane-associated state has only recently been described (Gao et al., 2020; Irwin et al., 2019).
Finally, the x-ray structure of two components of the inactivation complex of the visual
transduction pathway (RGS9-1/Gβ5L) have been reported (Cheever et al., 2008), but studies of
the related RGS7/Gβ5 complex (and the influence of the RGS7 binding protein (Patil et al.,
2018)) suggest that binding of RGS9-1/Gβ5L to the homologous R9AP scaffolding protein may
alter the molecular organization of this heterotrimeric inactivation complex. To summarize,
while there is detailed information about the components that comprise the photoreceptor
signalosome, there is a gap in our knowledge of the molecular architecture and structural
rearrangements of these signaling complexes residing on the membrane surface.
1.3 Use of phospholipid bilayer-coated nanoparticles (lipobeads) to reconstitute the
photoreceptor GPCR signaling pathway on membrane surfaces.
Supported phospholipid bilayers have been used for a variety of fundamental and applied
applications, including membrane biophysics, biosensors, cell-cell interactions, screening assays
of membrane proteins, and as drug-delivery vehicles (Chemburu et al., 2010; Crites et al., 2015;
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Ng et al., 2004; Troutier & Ladavière, 2007). Microspheres consisting of silica or polymeric
materials (e.g., hydrogels) have been used as the typical solid support for
forming unilamellar phospholipid bilayers whose size, density, membrane
curvature, and other biophysical properties can be optimized for their intended applications.
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B
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C

Figure 2-1. Reconstitution of the Gtα*-PDE6 activation complex on lipobeads. A. Lipobead
composed of silica nanoparticle coated with a unilamellar phospholipid bilayer. B. PDE6 (purple)
attached to lipobeads by their prenyl moieties. C. Addition of acylated Gtα* (red) to lipobeads with prebound PDE6 results Gtα* binding and the formation of the Gtα*-PDE6 activation complex.

We have utilized 70 nm diameter silica particles coated with a unilamellar lipid bilayer
(termed “lipobeads”) in order to tightly bind Gtα and PDE6 (both peripheral membrane proteins
containing lipophilic post-translational modifications) suitable for enzymological and structural
studies of the Gtα-PDE6 activation complex in a membrane-confined environment. (Fig. 2-1).
The ability to reconstitute in vitro the proteins comprising GPCR signalosomes on welldefined lipobeads enables the integration of biochemical, biophysical, and structural studies to
advance our mechanistic understanding of GPCR signaling pathways in the context of their
membrane environment.
2. Materials and Methods
Preparation of lipobeads.
Cationic phospholipids used for membrane attachment of PDE6 and Gtα were chosen
based on a previous study (Melia et al., 2000). 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC; Avanti Polar Lipids, Inc.) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP;
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Avanti Polar Lipids, Inc.) were dissolved in chloroform (molar ratio of 80:20) and
evaporated. Silica nanoparticles (70 nm diameter, 2.0 g/cm 3; DiagNano) were initially prepared
by resuspending 5 mg of beads (23 pmol) with HNM buffer (20 mM HEPES (pH 7.5), 100 mM
NaCl, 2 mM MgCl2) followed by centrifugation at 10,000 x g for 10 min, and resuspension
in 1.0 ml of HNM buffer. The dried phospholipids were mixed with the lipobead suspension to a
final phospholipid concentration of 5 mM. The mixture was gently vortexed for 2 min and
allowed to settle for 1 min; this process was repeated four more times. Unilamellar vesicles
coating the silica particles were formed by extruding the mixture fifteen times through a 0.1 µm
polycarbonate membrane using a Mini-Extruder (Avanti Polar Lipids, Inc.). The unbound
phospholipids were removed by several cycles of centrifugation and resuspension of
the lipobeads with HNM buffer.
Given the surface area of a 100 nm liposome (0.03 µm 2), a lipid headgroup area of 0.7
nm2 (Kučerka et al., 2006), and 5.0 nm for the thickness for the phospholipid bilayer (Marquardt
et al., 2016), we calculate that each lipobead contains ~80,000 phospholipids. Thus,
a lipobead concentration of 1 nM is equivalent to a total phospholipid concentration of
80 µM. Note that the surface-accessible phospholipid concentration (i.e., the outer monolayer) is
about ~50% of the total phospholipid concentration, as previously determined experimentally for
100 nm unilamellar liposomes (Malinski & Wensel, 1992).
Isolation and purification of PDE6 and Gtα from bovine retina.
Bovine rod PDE6 holoenzyme was isolated from bovine retinas (W.L. Lawson Co.) and
purified following standard procedures (Pentia et al., 2005). Gtα was extracted from PDE6depleted photoreceptor membranes by addition of 100 µM GTP immediately prior to
centrifugation (31,000 x g for 30 min); the process was repeated for a total of three extractions.
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The recovered Gtα containing bound GDP was then purified by affinity chromatography in
a HiTrap Blue HP column (GE Healthcare) as described previously (Ting et al., 1993), followed
by Superdex 200 (GE Healthcare) gel filtration chromatography. Both proteins were purified to
>95% homogeneity as judged by SDS-PAGE, stored in 50% glycerol at -20⁰ C, and bufferexchanged into the appropriate buffer before use.
Analytical procedures.
Protein, phospholipid, and nanoparticle quantitation.
The PDE6 concentration was determined based on knowledge of the k cat of the trypsin-activated
enzyme (5600 cGMP hydrolyzed per PDE6 per s (H Mou et al., 1999)). Other protein
concentrations were determined using the bicinchoninic colorimetric assay (Smith et al.,
1985)with bovine γ-globulin as a standard. The phospholipid content of lipobeads preparations
was quantified with a phospholipid assay kit (Millipore Sigma). Silica nanoparticle preparations
were characterized by flow cytometry using a Sony SH800Z Cell Sorter to verify the accuracy of
the manufacturer’s stated concentration of particles.
Enzymatic assay of PDE6 activation by Gtα.
PDE6-catalyzed hydrolysis of cGMP was quantified using a coupled enzyme assay relying on
colorimetric detection of inorganic phosphate (Cote, 2000). The extent of PDE6 activation by
Gtα was referenced to the maximum activity of the same concentration of trypsin-activated
PDE6 (Pentia et al., 2005).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
For characterization of protein purity, SDS-PAGE was performed using NuPAGE 4-12% BisTris gels (Invitrogen) and Precision Plus molecular weight standards (BioRad). For
characterization of chemically cross-linked samples that include high molecular weight
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complexes not well resolved on Bis-Tris gels, we used 4-12% Tris-glycine gels (Invitrogen)
and PAGERuler Plus protein ladder (Thermo Fisher). Excised protein bands were trypsindigested and their identity determined by mass spectrometry (Zeng-Elmore et al., 2014).
3. Results and Discussion
3.1 Characterization of liposome-coated silica nanoparticles (lipobeads)
Consistent with previous reports (Ross et al., 2011)we found that vortexing a dried
down mixture of DOPC and DOTAP (80:20) with an aqueous suspension of 70 nm silica
spherical particles and subsequent extrusion through a 100 nm membrane allowed for the
spontaneous formation of lipid bilayers coating the silica beads. Following sedimentation and
resuspension in buffer to remove unbound phospholipids, measurements of the
phospholipid content of the lipobead pellet showed that less than 10% of the silica particles
lacked a surrounding phospholipid bilayer. Lipobead preparations were determined to be stable
for at least three days after preparation, as judged by constant amounts of PDE6 and less than
20% loss of Gtα from the lipobeads over this time period. In summary, this preparation
of unilamellar membranes coating spherical silica nanoparticles offers several advantages over
liposomes, including a well-defined vesicle size (~100 nm diameter) and membrane curvature,
high particle density for ease of sedimentation, and enhanced stability.
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3.2 Reconstitution of the Gtα-PDE6 activation complex on lipobeads
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Figure 2-2. Binding of PDE6 to lipobeads. Lipobeads (0.46 pmol) are mixed with 40
μl of the indicated amount of PDE6 and incubated for 30 min. Following centrifugation,
the supernatant fractions are assayed for PDE6 activity to calculate the percent of total
PDE6 activity bound to the lipobeads. Data represent the mean ± S.D. (n = 3).

To examine the binding characteristics of lipobead preparations, we first quantified the
ability of the purified rod PDE6 holoenzyme to bind to lipobeads. The PDE6 heterotetramer is
composed of two catalytic subunits [PDE6A (Pα) and PDE6B (Pβ)] and two identical inhibitory
subunits [PDE6G (Pγ)] (Cote, 2021). The affinity of PDE6 for membrane association is
conferred by farnesyl (Pα) and geranylgeranyl (Pβ) groups at the C-terminus of each
subunit (Anant et al., 1992). Fig. 2-2 shows that 80% or more of the total PDE6 added
to lipobeads are pulled down when the protein-lipobead mixture is centrifuged. This result is
consistent with the high affinity with which PDE6 binds to rod outer segment membranes (Baehr
et al., 1979), and demonstrates that the binding capacity of lipobeads for PDE6 exceeds the
highest concentration tested in Fig. 2-2. When referenced to the membrane surface
area, 12 pmol PDE6 bound to lipobeads (~870 PDE6 per µm 2 of membrane) exceeds the surface
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density estimated of PDE6 on rod outer segment disk membranes (500 PDE6 per µm 2 (Pugh &
Lamb, 2000)). In addition to mimicking the in vivo density of PDE6 on the disk membrane,
the tethering of PDE6 to the phospholipid bilayer of lipobeads likely provides a physiologically
relevant conformation for the PDE6 holoenzyme to interact with its membrane-confined binding
partners.
The efficacy with which PDE6 can be activated by activated Gtα in vitro is greatly
enhanced when both proteins are tethered to either rod outer segment membranes (Fung,
1983) or liposomal preparations (Malinski & Wensel, 1992), especially those containing cationic
phospholipids (Melia et al., 2000). To evaluate the effectiveness of our lipobead preparation to
promote activation of PDE6 catalysis by activated Gtα, we incubated lipobeads (pre-incubated
with PDE6 holoenzyme) with increasing concentrations of Gtα-GDP to which aluminum
fluoride was added (to persistently activate Gtα by mimicking the terminal phosphate of
GTP (Bigay et al., 1985)). As seen in Fig. 2-3, PDE6 holoenzyme confined to lipobeads was able
to be fully activated by Gtα-GDP-AlF4- in a concentration-dependent manner whereas incubation
of PDE6 and Gtα in solution was much less effective. We were also able to show that increasing
the PDE6 density 10-fold on the lipobeads allows for more efficient activation of PDE6 by Gtα.
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Figure 2-3. Concentration-dependent enhancement of G-protein activation of PDE6 when
bound to lipobeads. PDE6 holoenzyme (either 0.2 nM or 2 nM) was incubated with 1.1 pmol
of lipobeads for 30 min at room temperature prior to the addition of the indicated amounts of
Gtα-GTPγS (Gtα*) for 45 min. Separate samples of PDE6 were mixed with Gtα* in the absence
of lipobeads. Upon addition of cGMP (2 mM final concentration), the extent to which PDE6
was activated by Gtα* was determined by monitoring degradation of cGMP. The extent of
activation by Gtα* is expressed as the percent of PDE6 activity measured when the inhibitory
Pγ subunits of PDE6 are removed by limited trypsin proteolysis. Data represent the mean ±
S.D. for 3 experiments (blue and black symbols; three black symbols without error bars are

In addition to providing a stable membrane environment for reconstituting the Gtα-PDE6
activation complex for biochemical studies, lipobead preparations can be used to investigate the
molecular architecture and structural rearrangements occurring upon the interaction of
activated G-protein α-subunits with their effectors at concentrations similar to those found in
vivo. We have previously used lipobeads to carry out chemical cross-linking and integrative
structural modeling to refine the x-ray structure of Gtα in its membrane-associated
conformation as well as the Gtα-PDE6 activation complex (Irwin et al., 2019). To further
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examine the stoichiometry of Gtα binding to PDE6 and the sequential mechanism of PDE6
activation (Qureshi et al., 2018), we conducted experiments at a low molar excess of Gtα to
PDE6 on lipobeads at elevated PDE6 concentrations. The lipobead-associated proteins were
chemically cross-linked with BS3, the protein complexes were subsequently resolved on a 412% Tris-glycine gel, and the identity of the proteins extracted from each band determined by
MS (Figure 2-4). Less than 6-fold molar excess of activated Gtα relative to PDE6 was sufficient
to observe cross-linked complexes of Gtα with individual PDE6 catalytic subunits (possibly also
containing bound Pγ) at ~140 kDa, as well as one and two Gtα molecules cross-linked to the
PDE6 holoenzyme that formed discrete bands at higher molecular weights.

Figure 2-4. Chemical cross-linking of the activated complex of Gtα and PDE6. Crosslinking of PDE6 and Gtα* was performed by first binding 9 pmol of PDE6 to 0.46 pmol
lipobeads for 20 min followed by centrifugation. The lipid pellet was resuspended with 115
pmol Gtα-GDP-ALF and incubated for 45 min followed by centrifugation. The pellet was
resuspended in 20 μl HNM buffer containing 0.125 mM BS3 and crosslinking proceeded for
45 min. Lane A contains purified PDE6, lane B contains purified Gtα*, and lane C contains
the crosslinked mixture.

25

4. Conclusions
Lipobeads provide many advantages over traditional liposomes. Similar to large
unilamellar vesicles, lipobeads have a well-defined and uniform size. This property helps to
control both membrane curvature as well as the ability to control the surface density of
membrane proteins. Secondly, lipobeads have mechanical stability as well as increased density
over traditional preparations of liposomes. This permits for the sedimentation of the lipobeads at
relatively low g-forces allowing for easy control of lipobead concentration as well as the ability
to remove unbound species from membrane bound-proteins.
In the context of visual transduction, we have shown that lipobeads present the same
activity enhancement as traditional liposomes while still allowing for the many advantages
mentioned above. The ability to increase PDE6 concentration on the membrane surface allowed
us the illustrate that activation efficiency is enhanced with relation to PDE6 density on the
membranes. This could allow for study of PDE6 activation at stoichiometric and
substoichiometric levels in the future which could have significant implications in the
understanding of the activation mechanism of PDE6.
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Chapter 3
THE MOLECULAR ARCHITECTURE OF PHOTORECEPTOR
PHOSPHODIESTERASE 6 (PDE6) WITH ACTIVATED G PROTEIN ELUCIDATES
THE MECHANISM OF VISUAL EXCITATION
Some of the content in this chapter was published in Journal of Biological Chemistry (Irwin et
al., 2019).
Authors: Michael J. Irwin, Richa Gupta, Xiong-Zhuo Gao, Karyn B. Cahill, Feixia Chu, Rick H.
Cote
Abstract
Photoreceptor phosphodiesterase (PDE6) is the central effector of the visual excitation pathway
in rod and cone photoreceptors, and mutations in PDE6 structure or regulation often result in a
variety of human retinal diseases. The rod PDE6 holoenzyme consists of two catalytic subunits
(Pαβ) whose activity is suppressed in the dark by binding of two inhibitory γ-subunits (Pγ). Upon
photoactivation of rhodopsin, the heterotrimeric G-protein (transducin) is activated, resulting in
binding of the activated transducin α-subunit (Gtα) to PDE6, displacement of Pγ from the PDE6
active site, and enzyme activation. Although the biochemical pathway is understood, the lack of
detailed structural information about the PDE6 activation mechanism hampers efforts to develop
therapeutic interventions for PDE6-associated retinal diseases. To address this, we used a crosslinking mass spectrometry approach to create a model of the entire interaction surface of Pγ with
the regulatory and catalytic domains of Pαβ in its nonactivated state. Following reconstitution of
PDE6 and activated Gtα with liposomes and identification of cross-links between Gtα and PDE6
subunits, the PDE6-Gtα protein complex was determined to consist of two Gtα binding sites
bound per holoenzyme. Each Gtα interacts with the catalytic domains of both catalytic subunits,
as well as inducing major changes in the sites of interaction of the Pγ subunit with the catalytic
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subunits. These results provide a structural model for the activated state of the PDE6-Gtα*
complex during visual excitation, thereby enhancing our understanding of the molecular etiology
of inherited retinal diseases.
Introduction
The photoreceptor cGMP phosphodiesterase (PDE6) is the central effector enzyme of the
G protein-coupled visual transduction pathway in vertebrate rod and cone photoreceptors. PDE6
is exquisitely regulated by a cascade of reactions beginning with photoactivation of the visual
pigment, opsin, and subsequent activation of the heterotrimeric G-protein, transducin, in the
signal-transducing outer segment of the photoreceptor cell. The activated transducin α-subunit
(Gtα) then binds to the membrane-associated PDE6 and accelerates its hydrolytic activity to
transiently lower cGMP levels in the photoreceptor outer segment. This results in the closure of
cGMP-gated ion channels and hyperpolarization of the membrane, leading to synaptic
transmission to other retinal neurons (Cote et al., 2021).
PDE6 belongs to the eleven-member phosphodiesterase enzyme superfamily that shares a
highly conserved catalytic domain responsible for the hydrolysis of the intracellular messengers
cAMP and cGMP (Bender & Beavo, 2006; Francis et al., 2011). In addition to the C-terminal
catalytic domain, the catalytic subunits of PDE6 consist of two N-terminal regulatory GAF
domains (GAFa and GAFb) that are also present in four other PDE families (Zoraghi et al.,
2004). However, PDE6 differs from the other ten PDE families in several important respects: (1)
unlike the other ten homodimeric PDE families (as well as cone PDE6), rod PDE6 is composed
of two different catalytic subunits, α and β, that form a heterodimer (Pαβ); (2) PDE6 catalysis is
uniquely regulated by an intrinsically disordered, 9.7 kDa inhibitory γ-subunit (Pγ) that interacts
with both the regulatory and catalytic domains of each catalytic subunit to form the nonactivated
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rod PDE6 holoenzyme (stoichiometry αβγγ); (3) rod and cone PDE6 are the only PDEs whose
activation directly results from binding of a G protein, specifically the activated Gt α subunit; and
(4) upon activation, PDE6 catalysis occurs at the diffusion-controlled limit, more than two orders
of magnitude larger than the catalytic turnover rate of other PDE families [reviewed in (Cote,
2006)].
Numerous biochemical approaches have been undertaken to understand the molecular
mechanism by which Gtα binds to the nonactivated PDE6 holoenzyme and relieves the inhibitory
constraint of Pγ on PDE6 catalysis. It has been conclusively demonstrated that in the
nonactivated state of the PDE6 holoenzyme, the C-terminal portion of Pγ binds to the catalytic
domain and blocks access of substrate to the enzyme active site (Barren et al., 2009; Granovsky
et al., 1997; Zhang et al., 2010). Catalytic activation of PDE6 is believed to result from
interactions of the switch II-α3-helix region of Gt α with the C-terminal region of Pγ that
displaces it from the catalytic pocket of PDE6 (Granovsky & Artemyev, 2001). This same region
of Pγ also modulates the GTPase activity of Gtα (Slepak et al., 1995) by potentiating the activity
of the regulator of G protein signaling-9 (RGS9) that binds to Gt α and Pγ in this inactivation
complex (Slep et al., 2001). Additional sites of interaction between the Gt α and the N-terminal,
polycationic, and glycine-rich regions of Pγ [reviewed in (Guo & Ruoho, 2008; Zhang et al.,
2012)] have been implicated in regulating the efficacy with which Gt α is able to activate PDE6
(Muradov et al., 2010; Wang et al., 2019; Zhang et al., 2010, 2012), as well as modulating the
affinity of cGMP for noncatalytic binding sites in the GAFa domain of the PDE6 catalytic
subunits (Cote et al., 1994; Mou & Cote, 2001; Norton et al., 2000).
Consistent with the demonstration of structural asymmetry in the binding interactions of
the two Pγ subunits with the rod PDE6 Pαβ heterodimer (Guo et al., 2005; Zeng-Elmore et al.,
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2014), complete activation of PDE6 by Gtα requires the binding of Gtα to two non-identical
binding sites on PDE6 [(Qureshi et al., 2018) and references cited therein]. Due to the limited
information on structure-function relationships of PDE6 holoenzyme in its nonactivated and Gtαactivated states, the molecular sequence of events by which Gtα binds to PDE6 to relieve the
inhibition of catalysis by Pγ at two different sites is not known.
Building on recent advances to determine the molecular architecture of the PDE6
holoenzyme at the atomic level using integrative structural modeling (Zeng-Elmore et al., 2014)
and cryo-EM (Gulati et al., 2019; Zhang et al., 2015), we present here a structural model for the
nonactivated PDE6 holoenzyme that includes the complete interaction surface of its inhibitory Pγ
subunits. We also provide a refined structural model for the membrane-associated structure of
Gtα and its association with Pγ, as well as the complex of the activated G-protein α-subunit (GtαGDP-ALF4-) with PDE6. In addition to elucidating the mechanistic basis of the first steps in
visual signaling, this work provides insights into the molecular etiology of retinal diseases
associated with mutations in transducin and PDE6.
Materials and Methods
Materials.
Bovine retinas were purchased from W.L. Lawson, Inc. The Mono Q, HiTrap SP Sepharose FF,
HiTrap Blue HP, and Superdex 200 columns were from GE Healthcare. The C18 reverse-phase
column (Proto 300, 4.6 × 250 mm) was from Thermo-Fisher Scientific. The primers for Pγ
mutagenesis and plasmid purification kits were from Invitrogen and Qiagen, respectively. The
QuikChange II Site-Directed Mutagenesis Kit was from Agilent Technologies. Phospholipids
and the Mini-Extruder were from Avanti Polar Lipids. Trypsin and Asp-N were purchased from
Promega. Silica particles (70 nm diameter, plain) were obtained from Advance Scientific.
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Chemical cross-linkers were from Thermo-Fisher, and all other reagents were from MilliporeSigma, Thermo-Fisher, or VWR.
Preparation of purified PDE6.
Rod PDE6 holoenzyme (subunit composition, αβγγ) was isolated from bovine rod outer
segments and purified by anion-exchange and gel filtration chromatography as described
previously (Pentia et al., 2005). The Pαβ catalytic dimer was prepared from purified PDE6
holoenzyme by limited trypsin proteolysis to selectively degrade the Pγ subunits; the time course
of proteolytic activation of PDE6 catalysis was empirically determined to ensure that > 90% of
the Pγ subunit was degraded without altering the apparent molecular weight of the catalytic
subunits on SDS-PAGE. Pαβ was then re-purified by Mono Q chromatography (Pentia et al.,
2005). Purified PDE6 preparations were stored in 20 mM HEPES, pH 7.5, 100 mM NaCl, 2 mM
MgCl2 (HNM buffer) plus 50% glycerol at -20 °C until use. Just prior to an experiment, the
protein was buffer exchanged and adjusted to the indicated concentration for the cross-linking
reaction.
PDE6 catalysis of cGMP hydrolysis was quantified using a coupled-enzyme assay with
colorimetric detection of inorganic phosphate (Cote, 2000). The PDE6 concentration was
estimated based on the rate of cGMP hydrolysis of trypsin-activated PDE6 and knowledge of the
kcat of the enzyme [5600 mol cGMP hydrolyzed per mol Pαβ per second (Mou et al., 1999)].
Preparation of persistently activated transducin α-subunit.
Gtα was selectively extracted from PDE6-depleted rod outer segment membranes by
adding either 50 µM GTPγS or 100 µM GTP to the ROS membranes and recovering the
solubilized Gtα following centrifugation of the membranes. Gt α was subsequently purified by
affinity chromatography on a HiTrap Blue HP column (Ting et al., 1993), followed by Superdex
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200 gel filtration chromatography to remove residual PDE6. The concentration of Gt α was
determined by a colorimetric protein assay (Smith et al., 1985) using bovine γ-globulin as a
standard. Purified Gtα was stored at -20 °C in 50% glycerol supplemented with 50 µM of GTPγS
or GDP until use. Prior to a cross-linking experiment, the Gtα-GTPγS or Gtα-GDP was buffer
exchanged into the appropriate cross-linking buffer. In the case of GDP-bound Gtα, the Gtα was
incubated with 30 µM AlCl3 and 10 mM NaF for 15 minutes on ice to form the activated GtαGDP-AlF4- complex (Deterre et al., 1986).
Expression and purification of Pγ mutants.
Pγ site-directed mutants were created with the codon-optimized wild-type bovine rod Pγ
sequence as the template and the QuikChange II Site-Directed Mutagenesis Kit to introduce
amino acid substitutions. The pET11a plasmids with the sequence-verified Pγ mutant sequences
were transformed into E. coli BL21(DE3) cells and grown at 37 °C in 2-YT media to an OD 600 of
~0.6. Then, 0.5 mM isopropyl β-D-1-thiogalactopyranoside was added and the cells incubated at
30 °C for 6 h. The recombinant Pγ protein was purified from the cell extract using a HiTrap SP
column followed by C18 reverse-phase HPLC (Artemyev et al., 1998). The apparent molecular
weight and purity (>95%) of the recombinant Pγ protein was verified by SDS-PAGE. Pγ cysteine
mutants were prepared as described previously (Zeng-Elmore et al., 2014). All Pγ mutants were
observed to inhibit Pαβ catalysis over the same concentration range as wild-type Pγ.
Preparation of liposomes and lipobeads to study interactions of transducin with PDE6.
Large unilamellar vesicles and sucrose-loaded vesicles (consisting of an 80:20 molar ratio of 1,2dioleoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-3-trimethylammonium-propane) were
initially utilized to improve the efficiency of transducin activation of PDE6 (Melia et al., 2000),
closely following established procedures (Wensel et al., 2005). To further improve the ability to
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quantitatively sediment PDE6 and Gtα attached to the liposomes (and to eliminate soluble
proteins), we adapted an existing method to prepare silica bead-supported liposomes [i.e.,
lipobeads; (Alkhammash et al., 2015)] for membrane association of PDE6 and Gtα. The ability
to pull down PDE6 (~90% PDE bound) and the enhancement of PDE6 activation by Gtα (up to
95% of maximum activation) were equivalent for all of the above liposome preparations.
Lipobeads were prepared by first washing 5 mg of 70 nm silica beads several times with
HNM buffer followed by centrifugation for 3 min at 15,000 x g. The bead pellet was then
resuspended in HNM buffer. 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-3trimethylammonium-propane were mixed at a molar ratio of 80:20 in chloroform, evaporated,
and resuspended in HNM buffer containing the lipobeads to a final phospholipid concentration
of 500 µM. Unilamellar vesicles coating the silica particles were formed by extruding the
mixture fifteen times through a 0.1 µm polycarbonate membrane using a Mini-Extruder.
Chemical cross-linking, in-gel digestion, and MS analysis.
Chemical cross-linking reactions were carried out following the manufacturer’s protocols for
each cross-linker. For cross-linking reactions with BS3, DSS, Sulfo-SDA, or Sulfo-MBS,
proteins were cross-linked in HNM buffer; for EDC cross-linking reactions, 100 mM MES
buffer, pH 6.5 was used. After the cross-linking reaction was quenched, proteins were
precipitated with trichloroacetic acid, separated by SDS-PAGE and visualized with Coomassie
Brilliant Blue G-250. For the case of the nonactivated PDE6 holoenzyme, a 50-fold molar excess
of the cross-linker was used, closely following the protocol of our previous study (Zeng-Elmore
et al., 2014).
To carry out cross-linking reactions with the complex of activated Gt α and PDE6
holoenzyme, PDE6 holoenzyme (10-50 pmol) was mixed with a 500-fold molar excess of Gtα33

GDP-AlF4- or Gtα-GTPγS along with 0.6 mg lipobeads. The mixture was incubated at room
temperature for 1 h and then spun at 10,000 x g for 1.5 min. Unbound proteins in the supernatant
fraction (~10% of the total PDE6 and ~50% of the Gtα) were discarded, and the lipobeadassociated proteins were resuspended and cross-linked for 1 h with the following molar excess of
cross-linker relative to PDE6: BS3 or DSS (500-fold), Sulfo-MBS (100-fold), Sulfo-SDA (100fold), or EDC (1000-fold). Following quenching of the cross-linking reaction with 20 mM Tris,
pH 7.5, the samples were spun at 5,000 x g for 1.5 min, resuspended in SDS-PAGE sample
buffer and loaded onto NuPAGE 4-12% Bis-Tris gels. Protein bands on the gel were visualized
with Coomassie Brilliant Blue G-250.
Cross-linked products were in-gel digested and analyzed by LC-MS and LC-MS/MS as
described previously (Zeng-Elmore et al., 2014), except that we also used Asp-N to generate
peptide fragments. For Asp-N digestions, 3 ng Asp-N were added to the gel pieces and incubated
for 18 h at 37 ⁰C. For proteolytic digestions with both enzymes, 300 ng trypsin was added to the
gel pieces for 4 h, then 3 ng of Asp-N was added and samples incubated for an additional 18 h.
The tryptic peptides were extracted as described (Zeng-Elmore et al., 2014), and Asp-N or
double digested peptide samples were extracted using 50% acetonitrile and 7% formic acid.
One microliter aliquots of the concentrated peptides were injected into the Dionex
Ultimate 3000 RSLC nano UHPLC system (Dionex Corporation, Sunnyvale, CA) and separated
by a PepMap RSLC column (75 µm × 25 cm, 100 Å, 2 µm) at a flow rate of 450 nl/min (mobile
phase A: 0.1% formic acid in H2O, mobile phase B: 0.1% formic acid in 80% acetonitrile). The
eluant was directed into the nano-electrospray ionization source of an LTQ Orbitrap XL mass
spectrometer (Thermo Scientific, Waltham, MA). LC-MS data were acquired in an informationdependent acquisition mode. Full MS spectra were acquired in the Orbitrap (m/z 315–2000). The
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five most intense ions were selected for collision-induced dissociation in the linear ion trap for
MS/MS data acquisition.
Identification of cross-linked peptides.
Cross-linked peptides were identified using an integrated module in Protein Prospector, using a
previously described strategy (Chu et al., 2010; Zeng-Elmore et al., 2014). Cross-linked peptide
scores were based on the number and types of fragment ions identified, in conjunction with the
sequence and charge state of the peptide. Only results where the score difference confirmed that
the cross-linked peptide match was better than a single peptide match alone were considered.
Expectation values were calculated based on matches to single peptides and thus were treated as
another score, rather than as a statistical measure of reliability.
Integrative structural modeling of PDE6, Gtα, and the Gtα-PDE6 activated complex.
Integral structural modeling was performed using the open-source Integrated Modeling
Platform (Webb et al., 2018) and Modeller (Sali & Blundell, 1993) in an iterative manner. To
perform rigid body docking of protein subunits, IMP was carried out in 2x10 4 Metropolis MonteCarlo sampling steps with a high temperature of 2.0, a low temperature of 0.5, and with a new
system configuration following each step. The top 100 scoring models were generated and saved,
and IMP was then used to perform clustering on the top 100 models in order to aid in model
selection. The best fitting model was run in Modeller using the same cross-linking restraints in
order to further refine the model, evaluate stereochemical quality, and fill in the missing atoms.
Secondary structure identification was initially determined by Pymol version 2.3 (Schrodinger)
and further refined and validated with Coot (Emsley et al., 2010).
The Pαβ catalytic dimer refinement was performed using the PDE6 cryo-electron
microscopic (EM) structure (Gulati et al., 2019) as the template (PDB ID: 6MZB). Structural
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model refinements used the spatial restraints imposed by cross-linked peptides we identified in
samples of native and reconstituted PDE6 catalytic subunits, as described previously (ZengElmore et al., 2014). Analysis of the root mean square deviations of our structural model with
other available structures was carried out using Visual Molecular Dynamics (VMD) software
version 1.9.3 (Humphrey et al., 1996).
To model the PDE6 holoenzyme (Fig. 3-1), the refined Pαβ model was used as a single,
unchanging rigid body and each Pγ subunit was treated as eight separate rigid bodies consisting
of residues 2-30, 31, 38-41, 44-45, 52-53, 58-62, 68, 70-87. This approach circumvented the lack
of uniform cross-linking data for the entire Pγ subunit. Two of the rigid bodies (residues 2-30
and 70-87) were based on the Pγ structure and topology obtained from the PDE6 cryo-EM
structure (Gulati et al., 2019). The remaining Pγ peptide fragments were generated in-silico
(http://www.arguslab.com/arguslab.com/ArgusLab.html) assuming a linearly extended
conformation. IMP was then used to dock the Pγ fragments. Subsequently, Modeller was used
with the same cross-linking constraints to fill in the missing portions of Pγ as well as to add the
missing atoms to each subunit.
The structure of membrane-associated Gtα-GDP-AlF4- was obtained using the x-ray
crystal structure of Gtα-GDP-AlF4- [1TAD; (Sondek et al., 1994)] as the primary template and
imposing distance restraints from cross-linked peptides we identified, as described above.
Because the cross-linking data of purified Gtα included cross-links from the N-terminal α-helix
of Gtα that is not included in the 1TAD crystal structure, the Gtα structure was refined by
including the N-terminal helix (amino acids 1-27) obtained from the transducin heterotrimer
structure (PDB ID: 1GOT) with the 1TAD structure as two rigid bodies for conducting
integrative modeling.
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The structure of Pγ docked to Gtα-GDP-AlF4- (Fig. 2) was performed by treating GtαGDP-AlF4- as a rigid body and dividing the central region of Pγ into 3 rigid bodies consisting of
residues 25, 39-41, and 45 in IMP. Modeller was used to refine the structure and add missing
atoms to the model.
The structure of the activated complex of Gtα and the Pαβ catalytic dimer (Fig. 3-3) was
docked using the previously described structures as templates. Pαβ was treated as a single rigid
body and two Gtα-GDP-AlF4- structures were included in the modeling in IMP, followed by
refinement with Modeller.
The input data files, modeling scripts and output models can be accessed at
https://github.com/rcotelab/Irwin-et-al-2019.
Results
Solution structure of the PDE6 catalytic heterodimer.
Upon comparing the 3.4 Å cryo-EM structure of the PDE6 holoenzyme (Gulati et al.,
2019) with our previous solution structure of PDE6 catalytic dimer determined by chemical
cross-linking, identification of cross-linked peptides by mass spectrometric analysis, and
integrative structural modeling (Zeng-Elmore et al., 2014), we observed that a number of
distance restraints defined by our cross-linking results were inconsistent with the cryo-EM
structure (e.g., cross-links in the β-subunit between residues 675 and 813, and between 675 and
815; Table 3-1). In addition, neither of the above-mentioned studies resolved the entire structure
of the Pγ subunits that are tightly bound to the PDE6 catalytic dimer in its nonactivated state. We
therefore performed integrative structural modeling of the bovine rod PDE6 holoenzyme using
the Gulati et al. cryo-EM structure as a template [PDB ID: 6MZB; (Gulati et al., 2019)] and the
previously reported (Zeng-Elmore et al., 2014) and new cross-linking data for the PDE6
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holoenzyme (Table 3-1) as inputs into the Integrated Modeling Platform (IMP) and Modeller
(see Materials and Methods) to determine the complete structure for the tetrameric PDE6.
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Exp. m/z
658.9788
431.8966
431.8969
405.4728
540.2943
606.6677
540.2935
530.9468
530.9463
567.6403
425.9827
606.6667
524.9417
573.6439

z
3

Δ (ppm)
7.4

pep1
Pβ

aa1
471

pep2
Pβ

aa2
475

crosslinker
EDC

3
3
4
3
3
3
3
3
3
4
3
3
3

-3.5
-2.8
2.9
2.3
1.7
0.81
2.4
1.4
-6.7
-5.2
0.034
-7.8
0.044

675
675
823
824
825
826
826
826
826
826
826
826
826

4

-6.9

1b

Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pα/Pβ
Pα/Pβ
Pβ
Pα/Pβ
Pβ
Pβ

813
815
832
832
827
828
829
831
445/444
442/441
828
444/443
832
78

EDC
EDC
EDC
EDC
Sulfo-SDA
EDC
Sulfo-SDA
Sulfo-SDA
Sulfo-SDA
Sulfo-SDA
Sulfo-SDA
Sulfo-SDA
Sulfo-SDA

578.0868

Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pβ
Pγ

479.7
474.8

4
2

-18
-18

Pγ
Pγ

C2c
C2c

Pβ
Pα

92
77

BMH
BMH

678.3601
1034.308
926.715

3
4
4

-9.4
2.5

4a
7d

Pβ

146

Pβ
Pα

184
383

EDC
BS(PEG)9

1134.087

4

0.73
15

Pγ
Pγ
Pγ

860.94

2

-3.6

Pγ
Pγ

C22f

Pβ
Pα

84
77

795.87
653.051

2
4

-12
-1.6

Pγ
Pγ

C22f
31e

Pα
Pβ

272
200

BMH
Sulfo-MBS

596.0509
1063.227
800.656

4
3
4

-15
-17
-8.8

Pγ
Pγ
Pγ

41a,g
44
44

4
3

-17
-15

Pγ
Pγ

52a,g
K62a,g

469
613/611
475
328/326

Sulfo-SDA
BS3
BS3

498.4935
911.4194

Pα
Pα/Pβ
Pβ
Pα/Pβ

911.4185
660.0972

3
4

-4.8
-1.3

Pγ
Pγ

K62a,g
K62a,d

Pβ
Pβ

450
446

879.7957

3

0.78

Pγ

K62a,d

Pα/Pβ
Pα/Pβ

394
393

478.512
670.0686
545.0488

4
4
4

0.34
-13

Pγ
Pγ
Pγ

K63a,h
K64g

Pα
Pβ

767
839

EDC
BMOE

K65g

Pα/Pβ

677/675

BS3

-7.6

C18e
C18e

BS3

Sulfo-MBS
BMH
BMH

EDC
EDC
EDC
EDC
EDC

Table 3-1. PDE6 holoenzyme intra- and inter-molecular crosslinked peptides. Crosslinked peptides were identified following chemical cross-linking of 10-50 pmol purified rod
PDE6 holoenzyme as described in Materials and Methods. Except where indicated with
superscripts, samples consisted of native PDE6 holoenzyme and were digested with trypsin prior
to mass spectrometric analysis: atrypsin/asp-N double digest; bSample consisted of
Pαβ reconstituted with recombinant, wild-type rod Pγ; cPαβ reconstituted with Pγ2C/68S;
d
Pαβ reconstituted with Pγ58K/62K/65K/73K; ePαβ reconstituted
with Pγ18C/68S; fPαβ reconstituted with Pγ 22C/68S; gPαβ reconstituted with
Pγ62K/65K/73K/79K, hPαβ reconstituted with Pγ53K/62K/65K/73K. Exp. m/z is the
experimentally measured mass-to-charge ratio, z is the charge state of the peptide, and Δ is the
accuracy measured in parts per million. The crosslinked peptides are defined as the protein
subunit (pep1, pep2) and amino acid residue number (aa1, aa2) identified using the indicated
crosslinker. In the “aa1” column, the presence of a single letter amino acid residue preceding the
residue number indicates an amino acid substitution of the wild-type Pγ sequence at the site of
cross-linking. In addition to the cross-links in this table, the PDE6 structural model included
spatial constraints from cross-links reported previously for the PDE6 holoenzyme (ZengElmore, 2014).
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As shown in Fig. 3-1A, the cross-link-refined solution structure of the PDE6 holoenzyme
fits well within the cryo-EM envelope (Gulati et al., 2019), with the spatial restraints imposed by
the cross-linking results generating a more compact arrangement of structural elements as well as
providing predicted structures for missing elements in the cryo-EM structure. Comparisons at the
level of individual domains of our cross-link-refined PDE6 solution structure with the cryo-EM
structure (Gulati et al., 2019) identified several significant differences in conformation: (1) the
N-terminal region preceding the GAFa domain in our structural model contains additional αhelical elements (Fig. S2B), consistent with the hypothesis (Gulati et al., 2019) that this region
may contribute to dimerization of the catalytic subunits. (2) Whereas the GAFa domains showed
relatively small differences in secondary structure when compared to the cryo-EM structure, the
GAFb domains of the PDE6 solution structure exhibited greater dissimilarity. Our cross-linking
restraints identified conformational differences in several loop structures of GAFb, including the
β1/β2 loop that contains a novel α2/α3 helix (data not shown); this loop is in close proximity to
the catalytic domain, and as previously suggested may play a role in inter-subunit allosteric
communication (Chu et al., 2019; Gulati et al., 2019). (3) The catalytic domains of our structural
model also exhibited significant differences in comparison with the cryo-EM structure,
particularly in the flexible H-loop and M-loop regions near the enzyme active site and in the α16
helix. Cross-links in the C-terminal region (Table 3-1 and ref. (Zeng-Elmore et al., 2014))
imposed spatial restraints to the conformation of the α15 and α16 helices in our model that
displaced these two helices toward the center of the catalytic domain (and are likely to contribute
to the observed conformation of the H- and M-loops), as well as defining additional α-helical
segments (Cα1 and Cα2) in the C-terminal region. The fact that the C-termini of the PDE6
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catalytic subunits are prenylated (Anant et al., 1992)and membrane-associated under our
experimental conditions likely account for the structural differences we observe in the catalytic
domain and C-terminus. Together, these observations emphasize the importance of chemical
cross-linking to define both
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Fig 3-1. Integrative structural model of the PDE6 holoenzyme. The structural model of
rod PDE6 holoenzyme (αβγγ) was determined by using the cryoEM structure 6MZB (Gulati,
2019) as a template and applying spatial restraints determined by chemical cross-linking of
purified bovine rod PDE6 (Table 3-1 and (Zeng-Elmore, 2014)). In the model, PDE6 subunits
are colored as follows: α-subunit, cyan; β-subunit, green; Pγ subunit primarily associated
with α-subunit (Pγ(α); red) and β-subunit (Pγ(β); deep purple). A. Superimposition of the
template cryoEM map (EMD-9297) with the cross-link refined structural model of
nonactivated PDE6 holoenzyme. B. Asymmetric interactions of Pγ with the Pαβ catalytic
dimer extending from the cGMP-binding GAFa domain to the GAFb domain and then
crossing over to the catalytic domain to the site of inhibition of catalysis. Each Pγ subunit
primarily interacts with one catalytic subunit. The two images are rotated 180 degrees. C.
Interaction surface of the Pγ(α) subunit with the PDE6 catalytic dimer. Pγ(α) residues
interacting with the catalytic dimer are shown as main chain atom spheres: red, residues
interacting with the α-subunit; pink, residues interacting with the β-subunit; and yellow, Pγ
residues that interact with both catalytic subunits; non-interacting Pγ(α) residues are shown as
red loops and α-helix. The catalytic subunit interacting residues are shown as a surface
representation (α-subunit, dark cyan; β-subunit, dark green). D. Interaction surface of the
Pγ(β) subunit with Pαβ. The interaction surface of the Pγ(β) subunit (180 degree rotation of
panel C) is depicted in which the deep purple, light purple, and orange spheres represent
interactions with the β-subunit, α-subunit, or both catalytic subunits, respectively.
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flexible structural elements (e.g., loops) and protein conformations unique to the membraneassociated state that are often challenging to resolve by more traditional structural methods.
Each intrinsically disordered Pγ subunit forms multiple interactions with both PDE6 catalytic
subunits.
In order to map the entire interaction surface of Pγ with the PDE6 catalytic dimer, we performed
cross-linking experiments with a variety of chemical cross-linkers as well as using several sitedirected mutants of Pγ that were reconstituted with Pαβ. The 21 new intermolecular cross-links
between Pγ and the α- or β-subunits (Table 3-1) along with previously reported cross-links
(Zeng-Elmore et al., 2014)) and the cryo-EM structure of two fragments of Pγ (Gulati et al.,
2019) permitted visualization for the first time of the molecular architecture of the entire PDE6
holoenzyme. Fig. 3-1B shows that the overall topology of the each Pγ subunit is similar,
originating at the noncatalytic cGMP binding pocket in the GAFa domain of one catalytic
subunit and terminating at the enzyme active site of the same catalytic subunit. While the N-and
C-terminal regions of Pγ assume a predominantly linearly extended conformation, the midregion of Pγ exists in a random coil conformation.
Analysis of the interaction surface of Pγ with the catalytic subunits (Figs. 3-1C-D)
reveals marked differences in the number and types of interactions of each Pγ with the two
catalytic subunits. One Pγ subunit (designated Pγ(Pα)) follows the trajectory of the α-subunit
(Fig. 3-1C), with approximately one-half of its 87 residues forming an interaction surface in the
GAFa, GAFb and catalytic domains, ending at the active site of the α-subunit. Nine Pγ(Pα)
residues interact with the β-subunit in its GAFa and GABb domains, with four of the nine being
in close proximity to both catalytic subunits. The second Pγ subunit (Pγ(Pβ)) has an even greater
interaction surface with the catalytic dimer (Fig. 3-1D), with 89% of its residues interacting with
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Pαβ. Pγ(Pβ) interactions with Pαβ include 62 residues of the β-subunit and 30 residues of the αsubunit, with 15 of these residues being in close proximity to both catalytic subunits. The large
number of Pγ(Pβ) interactions with the α-subunit is most evident in the GAFb domain where the
Pγ(Pβ) subunit comes into contact with the α-subunit GAFb domain (leftward projection in Fig.
3-1D), as well as multiple interactions of Pγ(Pβ) with the central α-helical “backbone” of both
catalytic subunits. This complex network of interactions of both Pγ subunits with both catalytic
subunits localized predominantly in the GAFb domains of the catalytic dimer may represent the
structural basis for allosteric communication between the α- and β-subunits during transducin
activation of PDE6 (see Discussion).
Structure of membrane-associated Gtα and its interactions with soluble Pγ.
We first carried out cross-linking experiments with activated Gtα attached to liposomes
to determine the solution structure of membrane-associated Gtα. Experiments were carried out
with Gtα-GDP-AlF4- for which a crystal structure is available (PDB ID:1TAD). For the Nterminal α-helix (αN) which is missing from this crystal structure [and proposed to have
conformational flexibility; (Zhang et al., 2004)], we used as a template the structure of the αN
helix that was determined for the inactive transducin heterotrimer (PDB ID:1GOT). With the αN
helix and the Gtα-GDP-AlF4- structures as templates and the intramolecular Gtα cross-links that
we identified (Table 3-2), a model of the membrane-associated, activated Gtα-GDP-AlF 4subunit of transducin was created (Fig. 3-2A). Intramolecular cross-links (K18 to K267 and E21
to K275; Table 3-2) between the αN helix and the Ras-like GTPase sub-domain of Gtα imposed
spatial constraints that are reflected in a major shift of the αN helix toward the αF/β2 loop region
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451.2427
451.2424
539.2929
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723.7675
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733.7522
899.8322
455.7341
576.6672
330.5199
658.381
817.4389
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3
3
3
3
3
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3
3
3
3
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3
3
3
4
3
3
2
2
3
3
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6.4
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7.3
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-7.9
-8.3
-8.3
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-9.1
-10
4.2
8
-3
-10
7.2
-10

pep1
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα

aa1
16
16
17
17
17
17
18
18
18
18
18
20
20
21
24
25
25
26
26
39
169
267
267
98
129
203
203

pep2
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Gtα
Pγ
Pγ
Pγ
Pγ

aa2
20
25
20
21
22
31
26
26
31
31
267
31
205
275
31
31
189
31
205
47
176
275
342
39
25
39
45

crosslinker
EDC
EDC
BS3
EDC
EDC
BS3
EDC
EDC
BS3
BS3
BS3
BS3
BS3
Sulfo-SDA
EDC
BS3
EDC
EDC
EDC
EDC
EDC
DSS
EDC
BS3
BS3
BS3
BS3

Table 3-2. Intra- and inter-molecular crosslinked peptides of membrane-associated GtαGDP-AlF4- and Pγ. Cross-linked peptides were identified following chemical cross-linking
of either lipobead-associated Gtα-GDP-AlF4- or Gtα-GDP-AlF4- incubated with a 2-fold
stoichiometric excess of purified Pγ and analyzed as described in Materials and Methods.
Abbreviations are defined in the legend to Table 3-1. All Gtα intramolecular crosslinks were
detected in both the absence and presence of Pγ.

that is part of the interface between the GTPase sub-domain and the helical insertion subdomain. This shift brings the αN helix in proximity with the nucleotide binding site. We
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conclude that the structural model shown in Fig. 3-2A better represents the membraneassociated, solution structure of Gtα in that it takes into account the N-terminal acylation of Gtα
responsible for its association with rod outer segment membranes in vivo.
Previous biochemical studies have identified two major regions of Pγ that bind to
activated Gtα, namely the polycationic central region of Pγ and the C-terminal half of Pγ
(Artemyev et al., 1993; Artemyev & Hamm, 1992; Guo & Ruoho, 2008; Slep et al., 2001; Zhang
et al., 2012; Zhang & Artemyev, 2010). To determine the topological relationship of Gtα with
Pγ, we incubated liposome-associated Gtα-GDP-AlF4- (see Materials and Methods) with purified
Pγ and conducted cross-linking analyses of the protein band migrating at the apparent molecular
weight expected for a 1:1 complex of Pγ and Gtα (~50 kDa). We identified five intermolecular,
cross-linked peptides spanning residues 25 to 45 of the central region of the Pγ molecule (Table
3-2) which interact with both the helical sub-domain and the Switch II region of the GTPase subdomain of Gtα (Fig. 3-2A). This 20 amino acid segment of Pγ interacts on the opposite face of
the Gtα subunit from the interface of Gtα with the PDE6 catalytic domain (see below). As seen in
Fig. 3-2B, Pγ assumes a highly extended linear structure when bound to Gtα compared with the
conformation of the same region of Pγ bound to the PDE6 α- or β-subunits. [Although there is
structural evidence that the C-terminal half of Pγ binds to the PDE6-facing side of Gtα (Grant et
al., 2006; Slep et al., 2001), our inability to observe cross-linked peptides between Gt α and this
region of Pγ arises from the absence of amino acid residues in the C-terminal half of Pγ capable
of generating cross-linked peptides for mass spectrometric detection (Zeng-Elmore et al., 2014).]
No significant changes in the tertiary structure of Gtα were detected upon Pγ binding.
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Fig 3-2. Structural model of Gtα-GDP-AlF4- and its interaction with Pγ in solution. A.
The structural model of Gtα was determined using the 1TAD crystal structure as the template
(Sondek, 1994) and refined with spatial restraints imposed from cross-linking results in the
absence or presence of Pγ (Table 3-2). Structural elements that were unchanged in the crosslink refined model are represented in green, with the conformational change of the αN helix
shown in brown (for the crystal structure) and blue (for the cross-link modified solution
structure). Also shown is the docked structure of Pγ (red) with Gtα-GDP-AlF 4- based on the
observed cross-linking results when Gtα associated with lipobeads was incubated with a 2fold molar excess of Pγ. Note that no significant changes in Gtα conformation were observed
upon Pγ binding. B. A comparison of the conformation of the central region of Pγ (residues
24 to 44, depicted as a gradient from blue to red spheres) when bound to Gtα or to the PDE6
catalytic subunits.
Molecular architecture of the G protein-effector activation complex.
Full activation of PDE6 by Gtα is greatly enhanced when both proteins are associated
with either rod outer segment membranes or are reconstituted with phospholipid bilayers
(Malinski & Wensel, 1992). In order to determine the structure of the transducin-PDE6 complex
in its membrane-associated state, we therefore pre-incubated purified proteins with cationic
phospholipid vesicles that have been shown to enhance PDE6 activation by Gtα (Melia et al.,
2000). To restrict our analysis to only membrane-associated Gtα and PDE6, we prepared
liposome-coated silica beads (“lipobeads;” see Materials and Methods) that allowed for
sedimentation of membrane-associated proteins for further analysis. Using this method, ~90% of
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the PDE6 holoenzyme was pulled down in the lipobead pellet, and under these conditions we
observed at least 80% of maximal activation of PDE6 catalysis by transducin (data not shown).
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Pα
Pα/Pβ
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Pγ
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aa2
a

442/440
826b
854b
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551
808/806
817b
807/805
620/618
326/328a
309c
807/805
307c
41
29
25
29

crosslinker
EDC
BS(PEG)5
BS3
BS3
EDC
Sulfo-SDA
BS3
BS3
Sulfo-SDA
BS3
BS3
BS3
EDC
BS3
EDC
BS3

Table 3-3. Intermolecular crosslinked peptides of the activated complex of Gt α-GDPAlF4- with PDE6 holoenzyme. Cross-linked peptides were identified following chemical
cross-linking of a mixture of Gtα-GDP-AlF4- and PDE6 holoenzyme attached
to lipobeads and analyzed as described in Materials and Methods. Abbreviations are defined
in the legend to Table 1. Superscripts indicate cross-links that were omitted from specific
structural models: aomitted during docking of Gtα to catalytic domain; bomitted during
docking Gtα to GAFb domain; comitted from computational modeling due to loop flexibility.
All identified intra- and inter-molecular cross-links involving PDE6 catalytic subunits were
identical to those observed in the holoenzyme structure [Table 3-1 and (Zeng-Elmore, 2014)]
and omitted here.
We first assessed whether all of the cross-linked peptides we observed between Gt α and
the PDE6 catalytic subunits could be accounted for by a single Gtα binding site per Pαβ. Table 3
shows that three PDE6 α-subunit-specific and three β-subunit-specific cross-links with Gt α ruled
out a single binding site per Pαβ, consistent with biochemical studies (Qureshi et al., 2018).
When 10 cross-linked peptides between Gtα and the α- or β-subunit of PDE6 in Table 3-3 were
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used as distance restraints for input into the IMP workflow, we found no single structural model
that was able to accommodate all of the cross-link restraints. Instead, we observed two major
classes of structural models with different cross-links that violated the distance restraints. The
predominant set of structural models was generated by omitting the two cross-links between Gt α
and the GAFb domains (Gtα9-Pα442/Pβ440 and Gtα24-Pα330/Pβ328; Table 3-3); the remaining
eight cross-links permitted docking of Gtα to two similar—but not identical—sites on the α- and
β-subunit catalytic domains (Fig. 3-3A).
Closer examination of the interface of Gtα with the PDE6 α-subunit catalytic domain
(Fig. 3-3B) revealed that the GTPase sub-domain of this Gtα molecule (including the Switch II
region and the αN helix) interacts with the α14 helix, the M-loop region [implicated in regulating
Pγ occlusion of the active site (Barren et al., 2009)] and the α15 and α16 helices of the α-subunit
catalytic domain, in excellent agreement with previous mutagenesis studies (Natochin et al.,
1998). Interestingly, the αB helix of this Gtα molecule interacts with the adjacent PDE6 β-subunit
in the linker region between the GAFb and β-subunit catalytic domain (Fig. 3-3B). The
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Fig 3-3. Model of Gtα-GDP-AlF4- docked to the Pαβ catalytic dimer. PDE6 holoenzyme
and Gtα-GDP-AlF4- bound to lipobeads (see Materials and Methods) were exposed to
chemical cross-linkers, and the identified cross-linked peptides between Gtα and PDE6
subunits (Table 3) were then used as spatial restraints for integrative structural modeling.
Two predominant clusters of models of the Gt α-Pαβ complex were generated, one with Gtα
docked to the two catalytic domains (with distance violations for Gtα24-Pα330/Pβ328, Gtα9Pα442, and Gtα9-Pβ440), the other with Gtα docked to the GAFb domains (with distance
violations for Gtα10-Pα854, Gtα17-Pα551, and Gtα128-Pα807/Pβ817). Due to insufficient
cross-links for Pγ in the activated complex, the inhibitory subunit is not shown. A. Structural
model of association of Gtα-GDP-AlF4- to the α-subunit [(Gtα(Pα), orange] and to the βsubunit [(Gtα(Pβ), blue] catalytic domains. B. Detailed view of the Gtα GTPase sub-domain
interface with the α-subunit catalytic domain, with the interaction surface of Gt α colored red
and the α- and β-subunit interacting residues colored magenta and brown, respectively. Black
sphere indicates Gtα Q200. C. Alternate docking of Gtα to the GAFb domains of the Pαβ
catalytic dimer (with the same orientation as in Panel A).
interaction surface of the second Gtα with the β-subunit was generally similar to the α-subunit,
but with a greater surface of interaction reflecting additional interactions with the region of the βsubunit linking the GAFb and catalytic domains. For both Gtα subunits, the N-terminal α-helix
has significant surface interactions with the catalytic domains. With the cross-links in Table 3-3,
we were unable to observe any significant changes in Gtα-GDP-AlF 4- conformation upon
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interaction with Pαβ. The same was true for the PDE6 catalytic dimer where the overall RMSD
for each catalytic subunit was ~1.0 A when comparing the nonactivated and transducin-activated
conformations of each PDE catalytic subunit (data not shown). Interestingly, the interaction
surface of Gtα with PDE6 catalytic subunits is similar to that observed for the complex of a
membrane-bound adenylyl cyclase with the Gs α-subunit, particularly in the Switch II and α3
helix regions of the GTPase domain (Qi et al., 2019).
A second cluster of structural models of Gtα-activated PDE6 docking with the GAFb
domain (Fig. 3-3C) was identified when three different cross-links at the bottom of the Pαβ
catalytic domains (Gtα10-Pα854, Gtα17-Pα551, and Gtα128-Pα807/Pβ805) were omitted during
the structural modeling (Table 3-3). Although insufficient cross-linking data for the Pγ subunit
precluded structural modeling of Pγ in the transducin-activated PDE6 complex, the same central
region of Pγ that binds to purified Gtα in an extended conformation (Fig. 3-2A) is associated
with the GAFb domain of nonactivated PDE6 (Fig. 3-1C-D) and likely promotes Gtα binding to
the GAFb domain shown in Fig. 3-3C. This second binding site for Gtα is supported by
biochemical studies indicating a role for the central region of Pγ in facilitating Gtα activation of
PDE6 catalysis (Zhang et al., 2010) as well as enhancing the dissociation of cGMP from GAFa
noncatalytic binding sites (Zhang et al., 2012).
Discussion
This paper reports the first complete structural models for the PDE6 holoenzyme (Fig. 31), the activated α-subunit of transducin in a complex with the inhibitory γ-subunit of PDE6 (Fig.
3-2), as well as the fully activated state of PDE6 in a complex with two transducin α-subunits
(Fig. 3-3)—all in their membrane-associated state that mimics the localization of the transducinPDE6 protein complex on photoreceptor outer segment disk membranes. Together, these
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structural models advance our understanding of the mechanism of visual excitation in rod
photoreceptors by revealing the asymmetric surface of interaction between each Pγ subunit and
the Pαβ catalytic dimer, as well as the different sites of interaction of Gtα with PDE6 and the
major conformational changes that the Pγ subunits must undergo upon transducin activation of
PDE6 in the phototransduction pathway.
Chemical cross-linking combined with mass spectrometric analysis (Chu et al., 2018) has
enabled us to refine the secondary, tertiary, and quaternary structure of PDE6 in its nonactivated
and transducin-activated states. The distance restraints imposed by cross-linked residues within
and between proteins comprising the nonactivated and activated states of PDE6 permitted us to
dock Gtα subunits to each catalytic subunit of PDE6, thereby providing a structural basis for the
allosteric mechanism for G-protein-coupled activation of PDE6 during visual excitation—
including the functional asymmetry of the PDE6 holoenzyme that underlies the requirement for
successive binding of two Gtα molecules for full enzyme activation (Lamb et al., 2018; Qureshi
et al., 2018) and references cited therein.] This cross-linking/mass spectrometric approach also
permitted visualization of flexible regions of the catalytic and inhibitory subunits that were
poorly resolved by cryo-EM (Gulati et al., 2019).
Our integrative structural modeling of PDE6 reveals the multiple inter-subunit
interactions that underlie the multi-faceted allosteric regulation of this G protein-activated
enzyme: (1) each Pγ subunit interacts with both PDE6 catalytic subunits, with lateral, crosssubunit communication likely transmitted through the GAFb domains where a number of Pγ
residues are in close proximity to both catalytic subunits (Fig. 3-1C-D); (2) the β-subunit exhibits
greater interactions with Pγ than the α-subunit, consistent with two classes of binding sites for Pγ
with Pαβ (Mou & Cote, 2001); (3) in addition to the extensive Pαβ dimerization surface, direct
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allosteric communication may occur between the β1/β2 loop in the GAFb domain of one
catalytic subunit and the catalytic domain of the other subunit (Gulati et al., 2019), as well as
between the catalytic domains and C-terminal regions of the two subunits (Fig. 3-1B).
Defining the molecular architecture of the transducin-PDE6 activated complex permitted
structural verification of the stoichiometry of two Gtα subunits bound to the PDE6 catalytic
subunits in its fully activated state, as well as unexpectedly revealing two distinct sites of
interaction of Gtα with the GAFb (Fig. 3-3C) and catalytic domains (Fig. 3-3A-B) of the PDE6
catalytic subunits. The observation that each Gtα subunit has sites of interaction with both the αand β-subunits of PDE6 is consistent with a cooperative activation mechanism in which the
binding of the first Gtα induces conformational changes in Pαβ that alter the ability of the
second Gtα subunit to bind to and trigger full enzyme activation (Lamb et al., 2018; Qureshi et
al., 2018).
Model for G protein activation of the central effector enzyme of the visual signaling pathway.
Fig. 3-4 presents a model consistent with our experimental results for the light-induced
activation of PDE6 holoenzyme by transducin that involves the sequential binding of two Gtα
subunits that results in both Gtα subunits releasing the inhibitory constraint of Pγ from its
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Fig 4. Proposed model for the activation of PDE6 by transducin during visual
excitation. A. In the dark-adapted condition, the PDE6 holoenzyme is inhibited by
its Pγ subunits occluding the enzyme active site (Fig. 3-1, rotated 90⁰). B. The first lightactivated Gtα subunit is proposed to initially bind to the GAFb docking site (Fig. 33C) without causing significant catalytic activation of PDE6 (Qureshi, 2018). The Pγ subunit
was docked to this complex using the following information: (1) the central region
of Pγ (gold) was docked using the cross-links obtained for the Gtα-Pγ complex (Table 3-2) in
conjunction with the cross-links used to dock Gtα to the GAFb domain (Table 3-3); (2)
lacking cross-linking data for the N-terminal region of Pγ in the activated complex, this
region of Pγ (purple) relied on PDE6 holoenzyme cross-links and thus its topology differs
from Fig. 3-1 only to the extent needed to accommodate cross-link spatial restraints imposed
by the Pγ central region; (3) in the absence of Pγ cross-links for its C-terminal region in the
activated complex, we modeled this region of Pγ (purple) interacting with Gtα using the
crystal structure of Pγ (residues 50-87) bound to a chimeric G-protein [PDB: 1FQJ; (Slep,
2001)]. C. Upon binding of a second Gtα, PDE6 becomes fully activated as both Gtα subunits
dock to the catalytic domains and displace the C-terminal region of Pγ from the enzyme
active sites. In order to accommodate the binding of the central region of Pγ to the helical
face (Table 3-2) and the C-terminal region of Pγ to the GTPase face of Gtα [Table 3-3 and
(Slep, 2001)], a major displacement of the N-terminal Pγ residues from
the GAFa domains must occur.
interactions with each PDE6 catalytic domain to cause full activation of PDE6 (Lamb et al.,
2018).
Upon light activation of the phototransduction cascade, nonactivated PDE6 holoenzyme
(Fig. 3-4A) is proposed to form initial interactions between the central region of Pγ (associated
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with the GAFb domains) and an activated Gtα subunit (Fig. 3-3C) resulting in the central region
of Pγ becoming significantly more extended (Fig. 3-4B). In this model, the binding of Gtα to this
central region of Pγ does not require major displacement of either the N- or C-terminal regions of
Pγ from its holoenzyme conformation. Upon binding of a second Gtα, Fig. 3-4C depicts a
relocation of the first Gtα from the GAFb to the catalytic domain, along with binding of the
second Gtα to the catalytic domain of the other catalytic subunit (Fig. 3-4C)—resulting in full
enzyme activation. As a consequence of Gtα binding to the central and C-terminal regions of Pγ
when docked to the catalytic domains, our model requires that the N-terminal region of Pγ
dissociate from its interactions with the GAFa domain (Fig. 3-4C). This structural model for
sequential activation of PDE6 is supported by prior biochemical and structural studies of Gtα
interactions with PDE6 subunits in the activated complex (Liu et al., 1999; Milano et al., 2018;
Natochin et al., 1998; Skiba et al., 1996; Slep et al., 2001). The required displacement of Pγ from
the GAFa domains is also consistent with a lowered affinity of cGMP to its GAFa binding sites
upon transducin activation of rod PDE6 (Norton et al., 2000; Zhang et al., 2012; Zhang &
Artemyev, 2010), as well as offering insights into differences in how rod and cone PDE6 may be
activated by transducin (Wang et al., 2019). Experimental support for the model in Fig. 3-4 is
currently under investigation, including validating the GAFb domain as an initial docking site for
one or both Gtα subunits, identifying whether the α- or β-subunit preferentially binds the first
Gtα, the allosteric communication pathway leading to binding of the second Gt α subunit, and the
significance of cGMP occupancy of the GAFa binding sites for the activation, recovery, and light
adaptation stages of visual transduction.
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Summary.
In addition to advancing a structural basis for understanding the initial events in the
visual signaling pathway, structural elucidation of PDE6 in its nonactivated and transducinactivated states offers insights into the molecular etiology of pathogenic mutations in these
proteins and possible therapeutic interventions. For example, having characterized the interaction
surface of Gtα-PDE6, it is now evident that the missense mutation (Q200E; black sphere in Fig.
3B) resulting in autosomal dominant congenital stationary night blindness (Szabo et al., 2007) is
located at the interface between the Gtα Switch II region and the PDE6 catalytic domain where
Pγ regulation of catalytic activation occurs. Since somatic mutations in PDE6 catalytic subunit
genes have been implicated in various cancers [(Maryam et al., 2019) and references cited
therein], understanding the atomic-level structure of PDE6 is also relevant to non-retinal
diseases. Given that abnormal accumulation of cGMP is believed to be the causative factor in
many retinal degenerative diseases (Power et al., 2020), understanding the structural organization
of PDE6 and the protein-protein interactions that regulate its activity may provide insights into
development of allosteric activators of PDE6 analogous to those being developed for other
members of the PDE family of enzymes (Baillie et al., 2019; Omar et al., 2019).
Acknowledgements
I thank my co-authors on this manuscript for all of their assistance. Sue Matte for purification of
protein, Karyn Cahill and Xiong-Zhuo Gao for crosslinking data and Pγ mutant purification, and
Richa Gupta for crosslinking data and VMD structural analysis.

56

Chapter 4
DETERMINATION OF THE SEQUENTIAL ACTIVATION OF PDE6 BY G-PROTEIN
α-SUBUNIT
Abstract
Photoreceptor phosphodiesterase is the central enzyme in the phototransduction pathway
in rod and cone photoreceptors. PDE6 is a heterotetramer, consisting of two catalytic subunits
(Pαβ) and two identical inhibitory subunits (Pγ). Upon light stimulation, an activation cascade
results in the binding of the activated G-protein transducin alpha subunit (Gtα*) to PDE6,
displacement of Pγ from the PDE6 active site, and enzyme activation. The biochemical pathway
has been well studied, however the structural basis for the activation mechanism has yet to be
elucidated. To address this gap, we used lipobeads to reconstitute PDE6 and Gtα* and
performed chemical crosslinking and mass spectrometric analysis of PDE6 interactions with
Gtα* at near physiological concentrations and at near stoichiometric and sub-stoichiometric
amounts of Gtα* to PDE6. This allowed for isolation of crosslinked species containing a single
Gtα* bound with very low activation, and two Gtα* bound to PDE6 with significant activation.
A single Gtα* is found to interact primarily with the regulatory GAF domains of PDE6. The
addition of a second Gtα* results in a shift in Gtα* binding, with both Gtα* now primarily
interacting with the two catalytic domains of Pαβ. These results support an activation mechanism
for PDE6, with Gtα* first interacting with the regulatory domains of PDE6 followed by a shift to
the catalytic domains and full activation of PDE6.
Introduction
The photoreceptor cGMP phosphodiesterase (PDE6) is the central effector enzyme of the
G protein-coupled visual transduction pathway in vertebrate rod and cone photoreceptors. PDE6
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is regulated by a cascade of reactions. Photoactivation of the visual pigment, opsin, is followed
by activation of the heterotrimeric G-protein, transducin, in the signal-transducing outer segment
of the photoreceptor cell. The activated transducin α-subunit (Gtα*-GTP) then binds to PDE6
and accelerates its hydrolytic activity to transiently lower cGMP levels in the photoreceptor outer
segment. This results in the closure of cGMP-gated ion channels and hyperpolarization of the
membrane, leading to synaptic transmission to other retinal neurons (Arshavsky & Burns, 2012).
PDE6 belongs to the eleven-member phosphodiesterase enzyme superfamily that shares a
highly conserved catalytic domain responsible for the hydrolysis of the intracellular messengers
cAMP and cGMP (Bender & Beavo, 2006; Francis et al., 2011). In addition to the C-terminal
catalytic domain, the catalytic subunits of PDE6 consist of two N-terminal regulatory GAF
domains (GAFa and GAFb) that are also present in four other PDE families (Zoraghi et al.,
2004). However, PDE6 differs from the other ten PDE families in several respects. Rod PDE6 is
composed of two different catalytic subunits, α and β, that form a heterodimer (Pαβ) and is
inhibited by a separate protein, Pγ. Additionally, upon activation, PDE6 catalysis occurs at the
diffusion-controlled limit, more than two orders of magnitude larger than the catalytic turnover
rate of other PDE families [reviewed in (Cote, 2021)].
Many biochemical studies have aimed to understand the molecular mechanism by which
Gtα* binds to the nonactivated PDE6 holoenzyme and relieves the inhibitory constraint of Pγ. It
has been conclusively demonstrated that in the nonactivated state of the PDE6 holoenzyme, the
C-terminal portion of Pγ binds to the catalytic domain and blocks access of substrate to the
enzyme active site (Barren et al., 2009; Granovsky et al., 1997; Zhang et al., 2010). Catalytic
activation of PDE6 is believed to result from interactions of the switch II-α3-helix region of Gt α
with the C-terminal region of Pγ that displaces it from the catalytic pocket of PDE6 (Granovsky
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& Artemyev, 2001). This same region of Pγ also modulates the GTPase activity of Gt α (Slepak et
al., 1995) by potentiating the activity of the regulator of G protein signaling-9 (RGS9) that binds
to Gtα and Pγ in this inactivation complex (Slep et al., 2001). Additional sites of interaction
between the Gtα and the N-terminal, polycationic, and glycine-rich regions of Pγ [reviewed in
(Cote et al., 2021)] have been implicated in regulating the efficacy with which Gtα is able to
activate PDE6 (Muradov et al., 2010; Wang et al., 2019; Zhang et al., 2010, 2012), as well as
modulating the affinity of cGMP for noncatalytic binding sites in the GAFa domain of the PDE6
catalytic subunits (Cote et al., 1994; Mou & Cote, 2001; Norton et al., 2000).
Building on recent advances to determine the molecular architecture of the PDE6
holoenzyme at the atomic level using integrative structural modeling (Irwin et al., 2019; ZengElmore et al., 2014) and cryo-EM (Gulati et al., 2019; Zhang et al., 2015), we present here a
structural model for the mechanism of activation of PDE6. This mechanism was elucidated
through the construction of homology models based on stoichiometric and sub-stoichiometric
crosslinking data, allowing for determination of the initial binding site of Gtα. In addition to
elucidating the mechanistic basis of the first steps in visual signaling, this work provides insights
into the molecular etiology of retinal diseases associated with mutations in transducin and PDE6.
Materials and Methods
Materials.
Bovine retinas were purchased from W.L. Lawson, Inc. The Mono Q, HiTrap SP
Sepharose FF, HiTrap Blue HP, and Superdex 200 columns were from GE Healthcare. The C18
reverse-phase column (Proto 300, 4.6 × 250 mm) was from Thermo-Fisher Scientific.
Phospholipids and the Mini-Extruder were from Avanti Polar Lipids. Trypsin and Asp-N were
purchased from Promega. Silica particles (70 nm diameter, plain) were obtained from Advance
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Scientific. Chemical cross-linkers were from Thermo-Fisher, and all other reagents were from
Millipore-Sigma, Thermo-Fisher, or VWR.
Preparation of purified PDE6.
Rod PDE6 holoenzyme (subunit composition, αβγγ) was isolated from bovine rod outer
segments and purified by anion-exchange and gel filtration chromatography as described
previously (Pentia et al., 2005). Purified PDE6 preparations were stored at -20 ⁰C in HNM buffer
consisting of 20 mM HEPES, pH 7.5, 100 NaCl, 2 mM MgCl 2 supplemented with 50% glycerol.
Just prior to an experiment, the protein was buffer exchanged and adjusted to the indicated
concentration for cross-linking or for activity measurements.
Preparation of persistently activated transducin α-subunit.
Gtα was selectively extracted from PDE6-depleted rod outer segment membranes by
adding either 50 µM GTPγS or 100 µM GTP to the ROS membranes and recovering the
solubilized Gtα following centrifugation of the membranes. Gtα was subsequently purified by
affinity chromatography on a HiTrap Blue HP column (Ting et al., 1993), followed by Superdex
200 gel filtration chromatography to remove residual PDE6. The concentration of Gtα was
determined by a colorimetric protein assay (Smith et al., 1985) using bovine γ-globulin as a
standard. Purified Gtα was stored at -20 °C in 50% glycerol supplemented with 50 µM of GTPγS
or GDP until use. Prior to a cross-linking experiment, the Gtα-GTPγS or Gtα-GDP was buffer
exchanged into the appropriate cross-linking buffer. In the case of AlF-activated Gtα, the Gtα
was incubated with 30 µM AlCl3 and 10 mM NaF for 15 minutes on ice to form the activated
Gtα-GDP-AlF4- complex (Deterre et al., 1986).
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Preparation of liposomes and lipobeads to study interactions of transducin with PDE6.
The detailed procedure for preparing lipobeads is described in Chapter 5 (Irwin et al.,
2022). Briefly, lipobeads were prepared by first washing 5 mg of 70 nm silica beads several
times with HNM buffer followed by centrifugation for 3 min at 15,000 x g. The bead pellet was
then resuspended in HNM buffer. 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-3trimethylammonium-propane were mixed at a molar ratio of 80:20 in chloroform, evaporated,
and resuspended in HNM buffer containing the lipobeads to a final phospholipid concentration
of 500 µM. Unilamellar vesicles coating the silica particles were formed by extruding the
mixture fifteen times through a 0.1 µm polycarbonate membrane using a Mini-Extruder.
Chemical cross-linking, in-gel digestion, and MS analysis.
Chemical cross-linking reactions were carried out following the manufacturer’s protocols
for the cross-linker BS3. Proteins were cross-linked in HNM buffer after which the cross-linking
reaction was quenched, proteins were precipitated with trichloroacetic acid, separated by SDSPAGE and visualized with Coomassie Brilliant Blue G-250. For the case of the nonactivated
PDE6 holoenzyme, a 50-fold molar excess of the cross-linker was used, closely following the
protocol of our previous study (Zeng-Elmore et al., 2014).
To carry out cross-linking reactions with the complex of activated Gtα and PDE6
holoenzyme, PDE6 holoenzyme (10-50 pmol) was mixed with lipobeads (0.46 pmol) followed
by centrifugation. Pellets were resuspended with a 0.4 or 3-fold molar excess of Gtα-GDP-AlF 4(for cross-linking) or Gtα-GTPγS (for activity assays) The mixture was incubated at room
temperature for 1 h and then spun at 10,000 x g for 1.5 min. Unbound proteins in the supernatant
fraction (~10% of the total PDE6 and ~50% of the Gtα) were discarded, and the lipobeadassociated proteins were resuspended and cross-linked for 1 h with the following 50 molar
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excess of cross-linker relative to PDE6 or BS3. Samples were quenched with sample loading
buffer and run of Tris-glycine gels. Protein bands on the gel were visualized with Coomassie
Brilliant Blue G-250 and excised.
Cross-linked products were in-gel digested with trypsin and analyzed by LC-MS and LCMS/MS as described previously (Zeng-Elmore et al., 2014). Tryptic peptides were extracted as
described (Zeng-Elmore et al., 2014).
One microliter aliquots of the concentrated peptides were injected into the Dionex
Ultimate 3000 RSLC nano UHPLC system (Dionex Corporation, Sunnyvale, CA) and separated
by a PepMap RSLC column (75 µm × 25 cm, 100 Å, 2 µm) at a flow rate of 450 nl/min (mobile
phase A: 0.1% formic acid in H2O, mobile phase B: 0.1% formic acid in 80% acetonitrile). The
eluant was directed into the nano-electrospray ionization source of an LTQ Orbitrap XL mass
spectrometer (Thermo Scientific, Waltham, MA). LC-MS data were acquired in an informationdependent acquisition mode. Full MS spectra were acquired in the Orbitrap (m/z 315–2000). The
five most intense ions were selected for collision-induced dissociation in the linear ion trap for
MS/MS data acquisition.
Identification of cross-linked peptides.
Cross-linked peptides were identified using an integrated module in Protein Prospector,
using a previously described strategy (Chu et al., 2010; Zeng-Elmore et al., 2014). Cross-linked
peptide scores were based on the number and types of fragment ions identified, in conjunction
with the sequence and charge state of the peptide. Only results where the score difference
confirmed that the cross-linked peptide match was better than a single peptide match alone were
considered. Expectation values were calculated based on matches to single peptides and thus
were treated as another score, rather than as a statistical measure of reliability.
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Integrative structural modeling of PDE6, Gtα, and the Gtα-PDE6 activated complex.
Integrative structural modeling was performed using the open-source Integrated
Modeling Platform (Webb et al., 2018) and Modeller (Sali & Blundell, 1993) in an iterative
manner. To perform rigid body docking of protein subunits, IMP was carried out in 2x10 4
Metropolis Monte-Carlo sampling steps with a high temperature of 2.0, a low temperature of 0.5,
and with a new system configuration following each step. The top 100 scoring models were
generated and saved, and IMP was then used to perform clustering on the top 100 models in
order to aid in model selection. The best fitting model was run in Modeller using the same crosslinking restraints in order to further refine the model, evaluate stereochemical quality, and fill in
the missing atoms. Secondary structure identification was initially determined by Pymol version
2.3 (Schrodinger) and further refined and validated with Coot (Emsley et al., 2010).
PDE activity assays
PDE6 catalysis of cGMP hydrolysis was quantified using a coupled-enzyme assay with
colorimetric detection of inorganic phosphate (Cote, 2000). The PDE6 concentration was
estimated based on the rate of cGMP hydrolysis of trypsin-activated PDE6 and knowledge of the
kcat of the enzyme [5600 mol cGMP hydrolyzed per mol Pαβ per second (Mou et al., 1999)].
To determine the enzyme activity at high concentrations of PDE6, 10µL of lipobeads
were mixed with the desired amount of PDE6 in HNM buffer. The PDE6 and lipobeads were
incubated at room temperature for 1 hour, followed by centrifugation at 10,000 x g for 10
minutes. The PDE6-containing pellets were resuspended in the desired molar excess of Gtα
(either -GDP or -GTPγS) in 40 µL HNM containing 2 µM vardenafil and incubated at room
temperature for 1 hour. Trypsinized and basal control samples were treated similarly, but did not
contain Gtα in the resuspension buffer. Following incubation, 40 µL of 4 mM cGMP was added
63

to each sample. In order to quench the reaction, 25 µL was transferred to a 96 well plate
containing 50 µL of 0.1 M HCl. The remainder of the assay was performed as described
previously (Cote, 2000).
Results
Reconstitution of the membrane-confined Gtα*-PDE6 activation complex at near physiological
concentrations
To determine the efficiency of transducin activation of PDE6 at concentrations
approaching those found in the rod outer segment, we first measured cGMP hydrolytic rates at
several PDE6 concentrations when reconstituted on lipobeads with approximately stoichiometric
amounts of either Gtα-GDP and Gtα-GTPγS. Fig. 4-1B shows that sub-stoichiometric levels of
Gtα-GTPγS do not activate PDE6 to a significant extent above basal levels even at the highest
concentration tested. However, with a 3-fold excess of Gtα*-GTPγS to PDE6, we observed
significant catalytic activation of PDE6 at the two highest PDE concentrations.
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Figure 4-1. Cross-linking and activity of PDE6 at near stoichiometric and substoichiometric concentrations of Gtα. Cross-linking and activity assays were performed as
described in Materials and Methods. A. Chemical crosslinking of 3:1 and 0.4:1 molar ratios
of Gtα*-GDP-AlF4- (75 and 60 pmol, respectively) to PDE6 (25 and 150 pmol, respectively).
Lane 1: Molecular weight ladder. Lane 2: 3:1 Gtα*:PDE6. Lane 3: 0.4:1 Gtα*:PDE6. B
Activation of PDE6 at set stoichiometric ratios of Gtα*-GTPγS or Gtα-GDP to PDE6 over a
range of 30-300 nM PDE6 .
In contrast, PDE6 activation was not observed when incubated with Gtα-GDP at either
0.4:1 or 3:1 ratios of Gtα:PDE6 except at the highest PDE6 concentration tested (Fig. 4-1B). At
300 nM PDE6, we did observe a small increase in activation induced by a 3-fold molar excess of
Gtα-GDP, consistent with earlier studies (Kroll et al., 1989). These results demonstrate that the
efficacy of Gtα* activation of PDE6 is greatly enhanced as the density of PDE6 and Gtα* on the
lipobead membrane approaches that of the rod outer segment membrane.
Sub-stoichiometric amounts of activated Gtα*-GDP-AlF4- relative to PDE6 results in binding of
one Gtα to either the Pα or Pβ GAFb domain
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The ability to reconstitute high concentrations of PDE6 and Gtα at defined molar ratios
on lipobead membranes in conjunction with separation of discrete Gtα-PDE6 complexes by
SDS-PAGE permitted us to determine whether sub-stoichiometric amounts of Gtα*-GDP-AlF 4were able to bind to the PDE6 holoenzyme (in the absence of catalytic activation). As seen in
Fig. 4-1A, lane 3, reconstitution of 0.4 Gtα*-GDP-AlF 4- per PDE6 holoenzyme on lipobeads and
chemical cross-linking led to the formation of a single cross-linked, high molecular weight
species migrating at a position indicative of a single Gtα bound to the PDE6 holoenzyme. This
band was isolated from the gel and processed for LC-MS analysis in order to identify crosslinked peptides. Using previously published structural models of Pαβ and Gtα as templates, the
two cross-linked peptides between Gtα*-GDP-AlF 4- and Pα and Pβ (Table 4-1) were used as
spatial restraints for integrative structural modeling of the interface of interaction between Gtα*-
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m/z
897.9128

pep1

3
3
3

912.0898
824.1034
915.4214

Gtα
Gtα
Gtα

3
4

917.0972
731.8498

Gtα
Gtα

Gtα

B
B

A
A

aa1
10

pep2
Pβ

aa2
195

313
42
25

Pβ
Pα/Pβ
Pβ

438
390/391
440

117
102

Pβ
Pα/Pβ

440
393/391

Table 4-1. Intermolecular cross-links of the sub-stoichiometric complex of Gtα-GDPAlF4- with PDE6. Cross-linked peptides were identified as described in Materials and
Methods. The crosslinked peptides are described using the protein subunit (pep1, pep2) and
the amino acid residue number (aa1, aa2). m/z is the measured mass to charge ratio and z is
the charge state of the peptide. The superscripts signify cross-links that provide specificity to
either the Pα (“A”) or Pβ (“B”) catalytic face.
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GDP-AlF4- and the Pαβ catalytic dimer. [Unfortunately, Pγ-containing cross-linked peptides
were present at levels below the detection limit.]

Figure 4-2. Homology model of a single Gtα-GDP-AlF4- bound to Pαβ. Pα is depicted in
cyan, Pβ is depicted in green, the Gtα interacting with the Pα catalytic face is depicted in
orange and the Gtα interacting with the Pβ catalytic face is depicted in blue. Homology
modeling was performed as described in the Materials and Methods. A 180° rotation is used
in order to show the docking site of Gtα on the opposite catalytic face.
As shown in Fig. 4-2, the Pα-specific and Pβ-specific cross-links with Gtα* revealed that
a single Gtα*-GDP-AlF4- had two similar but non-identical binding sites on opposite faces of
Pαβ, each one centered on the GAFb domains. The Gtα* subunits were oriented such that the αhelical sub-domain was in proximity to the GAFa and GAFb domains while the ras sub-domain
of Gtα* was oriented with the Switch 2 element pointing toward the catalytic domain H-loop that
regulates PDE6 catalysis. Although not resolved in this study, the polycationic, disordered
central region of Pγ subunit that traverses the GAFb domain is likely to be responsible for
stabilizing the binding of Gtα* to the GAFb region of the PDE6 catalytic dimer (see Fig. 4-6 in
Discussion). Since the PDE6 catalytic activity was not significantly different from its basal rate
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when sub-stoichiometric amounts of Gtα are present, we infer that the GAFb binding sites for
Gtα* do not interact with the C-terminal region of Pγ that is responsible for inhibition of
catalysis. In summary, under conditions where only a single Gtα*-GDP-AlF 4- binds to the PDE6,
the activity measurements and structural modeling both support a model in which the initial
binding event of transducin with PDE6 occurs at one of the two GAFb binding sites without
causing catalytic activation of PDE6.
When Gtα* is in molar excess to PDE6, Gtα localizes to the catalytic domains of Pα and Pβ and
is accompanied by activation of PDE6 catalysis
Analysis of the band corresponding to two Gtα*-GDP-AlF4- crosslinked to PDE6 (Fig.
4-1A, lane 2) resulted in a set of crosslinks (Table 4-2) consistent with docking of Gtα* to the
catalytic domains. Structural homology modeling using the crosslinks as spatial restraints
identified two distinct docking sites, one on each of the catalytic faces. All of the most likely
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Pβ
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3

844.3485

Gtα

3

916.0959

Gtα

Table 4-2 Chemical cross-links of the complex observed with an excess of Gtα-GDPAlF4- and PDE6. Cross-links were identified in the protocol detailed in the Materials and
Methods. Abbreviations are defined in Table 4-1.
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homology models generated by clustering analysis identified docking sites only at the catalytic
domains, not to the GAFb domains (Fig. 4-3).

Figure 4-3. Homology model of a 3:1 molar excess of Gtα-GDP-AlF 4- cross-linked to
PDE6. Subunit colors are defined in Fig. 4-2. Homology modeling was performed as
described in the Materials and Methods.
Similar to the homology models presented in Irwin et al. (2019), each Gtα has an
interface surface with each of the catalytic subunits (Irwin et al., 2019). Unlike the other
structural models described in this study, the homology models with a molar excess of Gtα-GDPAlF4- show asymmetry in the two docking sites. The Gtα* on the catalytic face of Pα shows
primary interactions with α12, α14 and the M-loop on the primary catalytic subunit, with
secondary interactions with several α-helical segments on the other catalytic subunit. The Gtα*
that primarily interacts with Pβ also interacts with α14 and the M-loop, but lacks interaction with
α12 and has an additional set of interaction with the Cα1 of Pβ. Additionally, this Gtα* molecule
has secondary interaction with the Pα GAFb domain as well as the helix in the Pα catalytic
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domain. A comparison to the model presented in Irwin et al. (2019) shows very similar docking
of Gtα* to Pα but significant difference in the docking site of Gtα* to the Pβ catalytic domain
(not shown).
Gtα-GDP binding to PDE6 interacts primarily with the GAFb domains but with reduced ability
to stimulate PDE6 activation
Because we (Fig. 4-1B) and others (Kroll et al., 1989) observed limited activation of
PDE6 when Gtα-GDP was present, we investigated the binding sites when sub-stoichiometric
amounts of Gtα-GDP were incubated with PDE6.
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Table 4-3. Chemical cross-links of the complex observed between sub-stoichiometric
Gtα-GDP and PDE6. Cross-links were identified using the protocol detailed in the Materials
and Methods. Abbreviations are defined in Table 4-1.
Cross-links identified under these conditions (Table 4-3) were used to create a homology
model, using the previously published structures for Pαβ and Gtα.as initial templates (Irwin et
al., 2019). All of the cross-links were consistent with a single binding site located on the Pβ
catalytic face of PDE6.
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Figure 4-4. Homology model of Gtα-PDE6 interactions with sub-stoichiometric (0.4:1)
amounts of Gtα-GDP relative to PDE6. Modeling was performed as described in the
Materials and Methods. Subunit colors are as defined in Fig. 4-2.
The cross-linking data for sub-stoichiometric amounts of Gtα-GDP relative to PDE6 resulted in a
structural model (Fig. 4-4) in which Gtα is localized to the mid-region of the catalytic dimer on
the same surface that interacts with the Pγ subunit associated with Pβ, referred to as the “Pβ
catalytic face”). Unlike the situation with activated Gtα*-GDP-AlF4-, there was no experimental
support from the cross-linking data for a second docking site for Gα-GDP on the Pα catalytic
face under these sub-stoichiometric conditions. The complex of Gtα-GDP with the Pβ catalytic
face has the helical sub-domain of Gtα extending to the GAFa domain of the Pβ subunit, while
the ras sub-domain of Gtα is inserted between the Pα GAFb and catalytic domains, with the
switch II region of Gtα forming close interactions with the H- and M-loops of the Pβ catalytic
domain. This model shows the αN helix of Gtα as the primary site of interaction with sites on
both Pα and Pβ (Fig. 4-4). Gtα is in close proximity to GAFb on Pα, with potential interaction
sites on the α1 and α2 helices as well as theβ2 strand and the β2/3 loop. The absence of catalytic
activation of sub-stoichiometric amounts of Gtα-GDP relative to PDE6 (Fig. 4-1B) suggests that
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the Pγ C-terminal region responsible for blocking access to the active site is not being displaced
when a single Gtα-GDP binds in this conformation.
When we prepared samples containing a 3-fold excess of Gtα-GDP, we observed a high
molecular weight band consistent with two Gtα bound. Analysis of the crosslinks (Table 4-4) led
to a structural model for Gtα-GDP binding to both catalytic faces. The structural models for two
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Table 4-4. Cross-links identified from the complex consisting of a 3:1 molar excess of GtαGDP to PDE6. Cross-links were identified using the protocol detailed in Materials and Methods.
Abbreviations are defined in Table 1.
Gtα-GDP bound to Pαβ show nearly symmetrical docking sites on each catalytic face (Fig. 4-5).
Both Gtα docking sites show primary interactions with GAFb for both subunits as well as
interaction with the catalytic domain with αN of Gtα as the primary interacting region. The
primary catalytic subunit has potential interaction at α2 and α5 as well as β5 on GAFb. In
addition, there is potentially significant interaction with the long helix (LH2) between GAFb and
the catalytic domains. Finally, interactions are predicted between Gtα helical sub-domain and
the H-loop as wells as α14, α15 and M-loop on the catalytic domain.
Each Gtα also has multiple interactions with the other catalytic subunit. This interaction
surface occurs at α2 and β2, β3, and the β2/3 loop on GAFb. Additionally, there is also potential
interaction with α11 on the catalytic domain. In a comparison with previously published
structures, this model shows significant similarity to the GAF docked structure published
previously [(Irwin et al., 2019); data not shown].
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Figure 4-5. Homology model produced from cross-links obtained from a structure
containing a 3:1 excess of Gtα-GDP to PDE6. Integrative modeling was performed as
described in the materials and methods. Colors of protein subunits are defined in Fig. 4-2.
Discussion
This work provides the first structural models for the Gtα*-PDE6 activation complex in
which a stoichiometry of one or two bound Gtα in both its inactive and activated states have been
characterized structurally and biochemically. These structural models advance our understanding
of the activation mechanism of PDE6 by elucidating the initial interaction site(s) between Gtα*
and PDE6 GAFb domains, as well as the interaction sites of activated Gtα* with the PDE6
catalytic domains in its activated state.
The combination of activity measurements along with homology models from
crosslinking experiments performed at high, membrane-confined protein concentration
represents a significant advance in the mechanism by which Gtα binding to PDE6 leads to its
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activation. This work also poses interesting questions with regards to the subsequent mechanism
of deactivation of PDE6. Combining the crosslinking measurements with activity measurements
demonstrates that binding of a single Gtα* to the PDE6 GAFb domains does not lead to
significant catalytic activation. Under conditions where two Gtα* are bound to PDE6,

Figure 4-6. Proposed activation mechanism of PDE6 activation by Gtα based on
homology models produced by cross-links for complexes with single and doubly bound
Gtα*. A single Gtα binds at the GAFb domain but does not relieve Pγ inhibition. Upon the
binding of a second Gtα, both migrate to the catalytic domains relieving the inhibition of both
Pγ simultaneously. A. The structure of Pγ was placed on the Gtα-GDP-AlF 4- substoichiometric structure using Figure 2 and the position of the non-activated state (Irwin et
al., 2019) and the cross-links between Gtα and Pγ for positions 25-45 (Irwin, 2019). B. The
structure of Pγ was placed on the Gtα-GDP-AlF 4- structure using Figure 3 and the position of
the activated state (Irwin et al., 2019) and the cross-links between Gtα and Pγ for positions
25-45 (Irwin et al., 2019).
significant activation of catalysis correlates with both Gtα* molecules being docked with the
catalytic domains of Pαβ.
From these results, we propose an activation model in which the initial site of interaction
of Gtα* is at the GAF domains (Fig. 4-6A). Upon the binding of a second Gtα*, both Gtα*
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localize to the catalytic domains resulting in removal of the C-terminus of Pγ and activation of
PDE6 catalysis (Fig. 4-6B). The shift in Pγ crosslinking observed in Irwin et al. (2019) suggests
that both Gtα* initially interact with PDE6 at the GAF domains and the resulting migration of
Gtα* results in the dislocation of Pγ from its interaction sites with the GAFa domain. This
proposed displacement of Pγ from GAFa is supported by biochemical studies showing that the
affinity of noncatalytic cGMP binding to GAFa is reduced upon Gtα activation of PDE6 (Zhang
et al., 2012).
Comparison of the structural model of two Gtα-GDP bound to the GAFb domains (Fig.
4-5), with the limited catalytic activation of PDE6 (Fig. 4-1B) also provides structural insights
into the previously observed ability of high concentration of Gtα-GDP to induce limited
activation of PDE6 catalysis (Kroll et al, 1989). The limited interaction of Gtα-GDP with the
catalytic domains that we observed may be sufficient to weaken the interactions of the Pγ Cterminus with the PDE6 active site without completely displacing Pγ occlusion of substrate
access to the active site.
This model also raises interesting questions with regards to the role of the RGS9-1
inactivation complex in accelerating transducin’s GTPases activity and leading to the
dissociation of Gtα-GDP from its PDE6 binding sites. The ability of Gtα-GDP to bind PDE6 at
sub-stoichiometric and stoichiometric amounts of Gtα relative to PDE6 suggests that the
deactivation mechanism of PDE6 likely requires active displacement of the Gtα-GDP following
hydrolysis of GDP.
In addition, understanding visual signaling on a structural level is essential to
understanding disease causing mutations. Irwin et al (2019) reported on sites at the interaction of
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PDE6 and Gtα which have been implicated in congenital stationary night blindness, and that
interaction surface was also seen in this work. Being able to distinguish mutations that are likely
interfering at different stages of the activation mechanism will be essential to developing
pharmaceutical regulators of PDE6 aimed at treating retinal diseases.
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Chapter 5
ASSEMBLY OF THE PDE6 INACTIVATION COMPLEX ON LIPOSOME-ENCASED
SILICA PARTICLE (“LIPOBEAD”) SURFACE
Abstract
The deactivation of PDE6 involves binding to a protein complex containing Regulator of Gprotein Signaling 9 (RGS9-1) and G-protein β subunit-5 (Gβ5L) anchored to the membrane with
the RGS-9 anchoring protein (R9AP). The C-terminal region of Pγ is essential for the interaction
of RGS9-1 with the transducin α-subunit (Gtα), the result of which is the inactivation of Gtα and
thus PDE6.(Slep et al., 2001; Slepak et al., 1995) To study this inactivation complex, I developed
a protocol that integrates R9AP into lipobeads (called “proteolipobeads”) which allows for the
study of the deactivation complex bound to membranes. My preliminary data demonstrates that
proteolipobeads bind to purified RGS9/Gβ5 and are able to bind PDE6 and Gtα. I have also
optimized separation of proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) to resolve all of the individual proteins and their cross-linked complexes for future
determination of the molecular architecture of the PDE inactivation complex.
Introduction
Like all other heterotrimeric G protein α-subunits, the activated Gtα has an intrinsic GTPase
activity that hydrolyzes bound GTP to GDP, leading to reassociation with the transducin βγ
dimer to re-form the inactive, heterotrimeric G-protein. Since PDE6 activation is directly
dependent on association with Gtα-GTP, the lifetime of PDE6 activation is dictated by the
GTPase rate of Gtα. However, the intrinsic rate of GTP hydrolysis by transducin α-subunit is too
slow by ~100-fold to control signal termination of the photoresponse (Arshavsky & Pugh, 1998),
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and this observation led to evidence for the existence of a GTPase accelerating protein (GAP)
(Arshavsky et al., 1989; Arshavsky & Pugh, 1998)
The GAP responsible for transducin regulation during the visual signaling pathway
consists of a complex of three proteins, RGS9-1, its obligate binding partner Gβ5L, and the
integral membrane anchoring protein R9AP (Hu & Wensel, 2002). R9AP is a transmembrane
protein that enhances the ability of RGS9-1/Gβ5 to inactivate Gtα by increasing the rate of GTP
hydrolysis (Baker et al., 2006; Hu & Wensel, 2002; Lishko et al., 2002) and also protects RGS91/ Gβ5L from intracellular proteolysis [Figure 5-1 (Cote, 2021) (Keresztes et al., 2004; Krispel et
al., 2006)].

Figure 5-1. Model of the inactivation mechanism presented in Cote 2021.

Under most conditions, the rate-limiting step for recovery of the photoresponse in rod and
cone photoreceptors is the inactivation of the Gα-PDE activated state that is regulated by RGS91 and its binding partners. RGS9-1 is a photoreceptor-specific splice variant of the R7 subfamily
of RGS proteins(Anderson et al., 2009) . The RGS9-1 domain organization (Fig. 5-1) consists of
an RGS catalytic domain (responsible for its GAP activity), a G protein γ-like (GGL) domain
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that interacts with the Gβ5L protein (a member of the G protein β-subunit family), and the Nterminal DEP (Dishevelled, Egl10, Pleckstrin) and DEP helical extension (DHEX)
domains(Cheever et al., 2008). The DEP domain is believed to interact with R9AP. The PDE6
Pγ subunit is known to potentiate the intrinsic GAP activity of RGS9-1, with enhancement of
GAP activity occurring when Gα is reconstituted with the entire RGS9-1/Gβ5 heterodimer
(Cheever et al., 2008). Binding of R9AP to RGS9-1/Gβ5 is reported to further enhance GAP
activity by a distinct mechanism (Cheever et al., 2008). In addition, reversible phosphorylation
of RGS9-1 near its C-terminus and/or other light-dependent reactions have been suggested to
influence R9AP binding affinity and/or potentiation of GAP (Patil et al., 2018).
The molecular architecture of the RGS9-1 heterotrimer has not been reported, and little is
known about the conformational changes that regulate the GAP activity of RGS9-1 upon binding
to the activated Gα-PDE6 complex. The fact that the maximum GAP activity of the RGS9-1
heterotrimer is greatly enhanced when R9AP is membrane anchored suggests that the structural
model of the lipobeads-attached RGS9-1 heterotrimer complexed with activated Gα-Pγ will
provide novel insights when compared to previously reported solution structures (Slep et al.,
2001).
Materials and Methods
Recombinant protein expression and purification of RGS9-1, Gβ5L, and R9AP.
Mouse RGS9-1 and Gβ5L were co-expressed in the baculovirus expression system as
described by Skiba et al. (Skiba et al., 2001).Briefly, SF9 cells were grown to a density of 1-2 x
106 cells/mL in SF900 II SFM media (Thermo Fisher) containing 0.1% Pluronic, 2% fetal bovine
serum, and 50 µg/mL gentamicin at 27°C. Cells were co-infected with recombinant baculovirus
for RGS9-1 and Gβ5L (a gift from Dr. Kirill Martemyanov) at a multiplicity of infection of 3,
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harvested after 72 h and the cell pellet stored at -80°C until use. Cell pellets were resuspended in
20 mM Tris-HCl (pH. 8.0), 150 mM NaCl, and mammalian protease inhibitor cocktail (Millipore
Sigma) and sonicated for 10 sec followed by 40 sec of incubation on ice for a total of 5 cycles.
Following centrifugation (100,000 x g for 1 h) the supernatants were loaded onto a 1 mL Ni 2+NTA affinity column. After washing the column with the isolation buffer containing 20 mM
imidazole, the RGS9-1/Gβ5L dimer was eluted with a linear gradient of 20 to 500 mM
imidazole. The pooled protein was buffer-exchanged and then added to a Mono S column
(Cytiva) and eluted with a 0.1 to 0.4 M NaCl gradient. The purified RGS9-1/Gβ5L dimer was
stored at -20⁰ C in the isolation buffer containing 40% glycerol (Fig. 5-2).

Figure 5-2. Purification of RGS-1/Gβ5L. Purification performed as described in Materials
and Methods. Lane 1 pooled NiNTA purified RGS9-1/Gβ5L. Lane 2 pooled MonoS purified
The coding sequence for mouse R9AP was subcloned into the pET47b vector containing
a 6-histidine tag and transformed into Escherichia coli BL21/DE3 cells. Expression and affinity
purification of R9AP closely followed Hu and Wensel (Hu & Wensel, 2004). Affinity-purified
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R9AP was further purified by Superdex 200 chromatography with the mobile phase consisting of
300 mM NaCl, 25 mM Tris (pH 8.0), 2 mM dithiothreitol, and 4% sodium cholate (Fig. 5-3).

Figure 5-3. Purification of R9AP. Purification performed as described in Materials and
Methods. Lane 1 detergent extracted R9AP. Lane 2 Ni-NTA elution sample. Lane 3 Ni-NTA
unbound sample. Lane 4 Superdex 200 gel filtration chromatography peak (pooled and
concentrated).
Preparation of R9AP-containing proteolipobeads.
To incorporate R9AP into the phospholipid bilayer of lipobeads,
22 pmol of lipobeads were resuspended in 200 µl of 40 µM R9AP in the buffer used for R9AP
isolation. The mixture of R9AP and lipobeads were incubated with gentle mixing for 4 h at 4⁰ C,
and then diluted to 1 ml with R9AP isolation buffer lacking sodium cholate. Following overnight
incubation with gentle mixing, the proteolipobeads were centrifuged at 10,000 x g for 10 min.
The R9AP-containing proteolipobead pellet was then stored at -80⁰ C until use.
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Protein binding to lipobeads and proteolipobeads.
R9AP proteolipobeads were resuspended in HMN buffer
containing equimolar amounts of the RGS9-1/Gβ5L obligate dimer and incubated for 15 min
prior to centrifugation. Unbound protein was discarded and the proteolipobead pellet containing
the R9AP/RGS9-1/Gβ5L heterotrimer was resuspended in HMN buffer.
To reconstitute the entire inactivation complex, the inactivation timer was prepared as
described above. PDE6 and Gtα were then bound as described previously (Irwin et al., 2019).
Briefly, PDE6 was incubated with the proteolipobeads for 30 minutes followed by centrifugation
at 10,000 x g for 10 minutes. The protein containing pellets were then resuspended in 40µL of
HNM buffer containing the relevant concentration of Gtα.
Evaluation of protein-protein interactions on lipobeads by chemical cross-linking and SDSPAGE.
For chemical cross-linking experiments with proteolipobeads, we minimized the sample volume
by incubating 10 µl of lipobeads (1.1 pmol) with RGS9-1/Gβ5L for 30 min prior to
centrifugation. The proteolipobead pellet was then resuspended in 25µL HNM buffer containing
a 25-fold molar excess of bis(sulfosuccinimidyl)suberate (BS3) to R9AP. The reaction was
allowed to proceed for 1 hour at room temperature and quenched by the addition of 1x gel
sample buffer.
Results and Discussion
Proteolipobeads containing the anchoring protein R9AP permit reconstitution of the RGS9-1
inactivation complex
To enable studies of the proteins that form the RGS9-1 inactivation complex on outer
segment membranes, we first incubated detergent-solubilized R9AP (an integral membrane
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protein) with lipobeads to incorporate R9AP into the phospholipid bilayer to
form proteolipobeads (see Materials and Methods). Unlike standard liposomal preparations
where incorporation of integral membrane proteins into lipid bilayers can result a portion of
the proteins incorrectly oriented in the membrane, the characteristics of
our lipobead preparations (70 nm silica core, ~100 nm total diameter of the bilayer) enhanced the
likelihood that R9AP would insert into the lipobeads with its cytoplasmic domain facing outward
on the exterior of the proteolipobead. The difference between the inner diameter of the liposome
and the outer diameter of the silica particle does not allow for sufficient space within the
proteolipobead to accommodate inverse R9AP anchoring. Additionally, the liposomes are not
fully solubilized, and thus only the transmembrane segment of R9AP is likely to pass through the
semi-permeable membrane.
Fig. 5-4 shows that R9AP can be incorporated into lipobeads (lane A), and that the
resulting proteolipobeads can pull-down the obligate dimer of RGS9-1 and Gβ5L (lane B). Note
that a minor fraction of R9AP running at a MW consistent with dimer formation is also
observed. Lane C shows both PDE6 and Gtα can also be pulled down in the presence of the
RGS9-1/Gβ5L/R9AP heterotrimer.
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Figure 5-4. R9AP proteolipobeads pulldown assay with RGS9-1/Gβ5L, Gtα, and PDE6.
A. R9AP proteolipobeads. B. R9AP proteolipobeads incubated with RGS9-1/Gβ5L. C. R9AP
proteolipobeasds with RGS9-1/Gβ5L, PDE6, and Gtα.
Upon incubation of the proteolipobead inactivation complex with the bifunctional crosslinker BS3, higher MW species are observed (Fig. 5-5) consistent with the formation of the
RGS9-1/Gβ5L dimer and the heterotrimer that also contains R9AP. Excision
and proteomic analysis of the indicated Coosmassie-stained bands confirmed the composition of
each protein band on the gel.

Figure 5-5. Crosslinking of the inactivation complex. Lane 1: R9AP proteolipobeads. Lane
2: R9AP, RGS9-1/Gβ5L pulldown. Lane 3 Crosslinking of R9AP with RGS9-1/Gβ5L with a
25-fold molar excess of BS3 to R9AP.
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Conclusions
This work provides the foundation and proof-of-principle for use of XL-MS to study the
PDE6 inactivation complex. We have determined that the existing lipobead protocol (see
Chapter 2) can be adapted to create stable R9AP-containing proteolipobeads. Theses
proteolipobeads have been shown to anchor RGS9-1/Gβ5L, as well as binding the peripheral
membrane proteins PDE6 and Gtα. Our preliminary cross-linking results also demonstrates that
the inactivation complex is forming on the proteolipobeads, with upper molecular weight bands
identified consistent with the sizes of crosslinked complexes expected from the inactivation
complex. Future work will be required to optimize the protocols as well as to ensure the
proteolipobeads are not having unexpected effects on the established protein-protein interactions
on lipobeads.
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Chapter 6
Conclusions and Future Work
Conclusions
Chemical cross-linking and mass spectrometry analysis of PDE6 has allowed the
structure of the PDE6 holoenzyme bound to lipobeads to be determined. Of particular note, this
methodology enabled docking of the full-length Pγ structure which was not completely resolved
by other structural models. The structure of the PDE6 heterotrimer shows the expected
interaction of Pγ with the GAFa as well as the catalytic domain, but also showed the central
region of Pγ to be very disordered and loosely associated with the GAFb and catalytic domains
of rod PDE6 catalytic dimer. This structure was then used as the basis for docking of the
activated G-protein α-subunit (Gtα). Our original model showed two distinct sets of docking
sites, one to GAFb and a second set to the catalytic domains. Our proposed sequential docking
mechanism involves Gtα first binding to the central region of Pγ located in proximity to the
GAFb domain, followed by binding of the original as well as a second Gtα subunit to the
catalytic domains, thereby relieving Pγ inhibition at both catalytic sites (Irwin et al., 2019).
This model was further strengthened by analysis of PDE6 with Gtα at near stoichiometric
and substiochiometric levels (3:1 and 0.4:1 respectively). Cross-links produced from the substoichiometric condition using Gtα-GDP-AlF4- identified a Gtα binding to either GAFb docking
sites of PDE6; activity measurements under similar conditions to the cross-linking experiments
indicated very little PDE6 activity with sub-stoichiometric amounts of Gtα per PDE6. Upon
addition of a slight excess of Gtα relative to PDE6, two Gtα were found to bind to the catalytic
domains accompanied by PDE6 catalytic activation. This work represents the most detailed
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analysis to date of the sequential mechanism for transducin activation of PDE6 (Chapter 3,
manuscript in preparation).
The lipobead preparation detailed in chapter 2 has allowed for the completion of crosslinking and PDE6 activity experiments at near physiological concentrations, allowing for use of
stoichiometric and sub-stoichiometric amounts of Gtα PDE6 where previously a large excess
was required. Additionally, the ability to prepare R9AP embedded in lipobeads
(“proteolipobeads”) provides a strong foundation for future studies of the molecular architecture
and sequential mechanism of the RGS9 inactivation complex. R9AP-containing proteolipobeads
have been shown to bind RGS9-1/Gβ5L to form the trimeric complex, as confirmed by
preliminary chemical cross-linking experiments. The R9AP proteolipobeads were also able to
bind PDE6 and Gtα, thus demonstrating “proof of principle” for future studies of the protein
complex that controls the rate of recovery of the photoresponse in rod photoreceptors.
Future Work
Future work for the analysis of the activation complex will require new techniques in
order to understand the dynamic movement of proteins (especially the intrinsically disorder Pγ
subunit) during formation of the PDE6 activation and inactivation complexes. For example,
hydrogen deuterium exchange with mass spectrometry analysis (HDX-MS) will allow analysis
of the protein dynamics occurring during the activation of PDE6, which will elucidate the
movements of Pγ upon Gtα binding and catalytic activation of PDE6. Elucidation of the
movement of Pγ and the orientation of Pγ during each of the states previously developed is
essential to enhancing our understanding of the PDE6 activation mechanism.
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In order to determine the structure of the inactivation complex, our current chemical
cross-linking coupled with LC-MS (XL-MS) will provide the first structural analysis of this
assemblage of PDE6, Gtα, and the heterotrimeric RGS9-1/Gβ5L/R9AP. This experimental
approach will provide a strong framework for follow-up studies of the protein dynamics and
subunit rearrangements that accompanies the inactivation of Gtα and the subsequent re-inhibition
of PDE6 catalysis.
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Appendix 1: General workflow for chemical cross-linking/mass spectrometry experiments
utilizing Integrative Structural Modeling

Appendix Figure 1: Flow chart of cross-linking to homology modeling process. Mass
spectrometry RAW files were converted to MGF files using RawConverter 1.2.0.0
(http://fields.scripps.edu/rawconv/). Protein Prospector
(https://prospector.ucsf.edu/prospector/mshome.htm) or xiSEARCH
(https://www.rappsilberlab.org/software/xisearch/) was used for cross-link analysis. Pymol
was used for topological analysis, confirmation of structures, and distance restraint
confirmation. The Integrative Modeling Platform was used for modeling, clustering, and
precision analysis, and Modeller was used for structure refinement. Both JPRED and Pymol
were used for secondary structure prediction and assignment.
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Appendix 2: Workflow for performing Integrative Structural Modeling
A comprehensive tutorial for the Integrative Modeling Platform can be found here:
https://integrativemodeling.org/2.5.0/doc/manual/rnapolii_stalk.html. Sample scripts and all
output files can be found here: https://github.com/rcotelab/Irwin-et-al-2019. Specific
implementations of modeling can be found in the Chapter 3 Materials and Methods section.
The first step in integrative modeling is to identify the rigid bodies that will be involved
in the modeling. Rigid bodies are the overall structures that should stay together as a single
structure during modeling. You can also identify super rigid bodies and chains of super rigid
bodies which can give your model more overall flexibility. These are all added to your topology
file.
Within the topology file, you label each molecule in the model with a name, color, fasta
file, fasta name, pdb file, chain identifier, residue range, bead size, rigid body, super rigid body,
and chain of super rigid body. If including EM structural information, you also include the
residues per gaussian (gaussian mixture models are used to speed up approximation of electron
density of individual subunits) in the topology file. All of the identified structures and files need
to be present in a single data folder.
Once your topology file is formatted correctly, it can be called in the modelling script.
All files, including the topology file, should be present in your data directory. Rigid body
movement parameters as well as flexible bead movement are the initial parameters to be set
which sets the overall flexibility for the modeling. Next, you input a list of your rigid bodies,
super rigid bodies, and chains of super rigid bodies as identified in your topology file. Finally,
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you set the randomization of your initial conformation before sampling begins. The number of
frames is the number of samples run, typically 20,000.
For cross-linking information, files need to be formatted as CSV files. The column titles
for cross-linked peptides and residues are input and the relevant CSV is called. The cross-link
distance is set as a length. The slope can be set which impacts the scoring function of the crosslink distance. Higher values create a greater score penalty in the event of a cross-link that has a
distance violation in the final model.
Monte Carlo temperature is set to 1.0, minimum temperature is set to 0.5, maximum
temperature is set to 2.5, and the number of best scoring models is typically set to 100. Following
the completion of the script, the standard clustering script is run, analyzing the movement of the
chains that are of most interest.
Modeller is then run with the same set of crosslinks present in the IMP run. Modeller will
refine the model as well as add missing atoms to the structure, since the output from IMP is an αcarbon only model.
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